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Preface
M
illions of lives are saved each year through blood transfusions. However,
in many developing countries people still die owing to a lack of blood
and blood products while many millions more are at risk of being infected by untest-
ed blood transfusions. In many countries, the lack of adequate blood donor recruit-
ment services, combined with the high prevalence of infectious agents, leads to high
prevalence rates of infections in donated blood. Overuse and inappropriate use of
blood are also factors to be addressed. There is a need to work globally to ensure
that blood and blood products are safe, accessible, available at reasonable cost,
used appropriately and are provided within a sustainable health care system. This
impacts mostly on women, children and trauma victims, especially the poor.
Equitable and safe blood transfusion and injections are not readily available. This is
why they are the core of a vital, renewed programme within WHO, which we want to
strengthen to respond to the needs of all populations, and particularly the poor and
marginalized populations in the developing countries.
In most developing countries a lack of quality management for the safety of
blood and blood products, injections, diagnostic imaging, clinical and laboratory tech-
nology services adversely affects the quality of care to the patients. 
Furthermore, Blood Safety and Clinical Technology in most developing countries
suffer from a lack of finance, skilled manpower, inappropriate equipment and poor
quality management: medical equipment and devices are either not available, not
used or malfunctioning; consumables and reagents are lacking; and there is a dearth
of infection control and waste management systems.
Thus, within the overall goal of ensuring equitable access to safe blood, quality
care and affordable technology, particularly in developing countries, WHO’s objec-
tives are to: 
  Increase access to safe blood, blood products and safe health care
technologies
  Promote quality health care services that are supported by safe and cost-
effective technologies.
In the following pages, the global Blood Safety and Clinical Technology Strategy
is laid out. Included are brief descriptions of the key activities proposed in the areas
of quality and safety of blood and blood products, injection safety, diagnostic imag-
ing, clinical and laboratory technology services and medical devices. These activities
will result in:
✔ National, regional and global policies, plans and strategies which will improve
access, quality and safety of blood and blood products, infections, diagnostic
imaging and clinical laboratory services
✔ Systems developed leading to better coordinated, organised, managed and
funded blood transfusion programmes
✔ Access to safe blood in all main hospitals in more than 60% of developing
countries
✔ Reduction of diseases attributable to unsafe blood, unsafe injections, or lack of
access or unsafe use of diagnostic and health care technologies vi
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✔ Validated norms, standards and biological reference preparations 
✔ Upgraded technical expertise of national regulatory authorities for the
evaluation and control of blood products and related biologicals
✔ Knowledge and skills in the areas of blood transfusion medicine and clinical
technology including laboratory services and diagnostic imaging
✔ Information systems to monitor impact
✔ Global collaboration to build consensus on effective strategies to improve
blood safety and injection safety.
Under the key cross-cutting themes of policy, quality and safety, access and use,
we believe these activities are integrally coherent within the strategy, and that they
best respond to the expressed needs in the countries. The BCT Strategy is a compo-
nent of the new Health Technology and Pharmaceuticals Strategy, which is in turn
coherent and consistent with WHO’s overall corporate strategy, as will be described
below.
In many cases these activities are the very first steps on the long road to ensure
blood safety. Thus, they are designed as being progressive. There is a need to lay
down a foundation for the major efforts that are yet to come before everyone in the
world has access to safe blood, blood products and safe health care technologies,
and to quality health care services that are supported by safe and cost-effective tech-
nologies.
Dr. Jean C. Emmanuel
Director, Blood Safety and Clinical Technology
Health Technology and Pharmaceuticals
Geneva, May 20011
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Introduction —
Blood Safety and Clinical
Technology 
T
he department of Blood Safety
and Clinical Technology was
established in 1998 as part of WHO’s
new cluster on Health Technology and
Pharmaceuticals (HTP). Its mission is to
promote the safety, quality and adequa-
cy of blood and blood products, injec-
tions, diagnostic and clinical technolo-
gies, and medical devices that are
essential for the provision of health
care. 
BCT and WHO’s
corporate strategy
Blood safety has been accorded a high
priority by the Director General, and is
an issue of concern to many WHO
Member States in the developed world
and all of the developing countries.
Acknowledging the importance of blood
safety, the World Health Day theme for
the year 2000 was “Safe Blood Starts
with Me – Blood Saves Lives”.
WHO’s four corporate strategic direc-
tions are:
  To reduce excess mortality,
morbidity and disability,
especially in poor and
marginalized populations
  To promote healthy lifestyles and
reducing factors of risk to human
health that arise from
environmental, economic, social
and behavioural causes
  To develop health systems that
equitably improve health
outcomes, respond to peoples’
legitimate demands, and are
financially fair
  To develop an enabling policy
and institutional environment in
the health sector, and promoting
an effective health dimension to
social, economic, environmental
and development policy. 
The following figure illustrates how
the priority activities in the BCT Stra-
tegy contribute to WHO’s four strategic
directions.
This same summary diagram can
be drawn for each of the departments
in the Health Technology and
Pharmaceutical Cluster, and is a con-
vincing statement of the coherence of
BCT Strategy with that of HTP and WHO
as a whole. 
4. Developing an enabling policy and institutional
environment, and promoting an effective health
dimension in development policies:
by developing global norms and standards and support national policies for 
blood products and appropriate health technology,and within the framework of 
agreed plans of action.
2. Reducing the leading
risk factors to 
human health:
by creating a safe environment for the
use of blood and blood products,
injections,thus reducing the risk of
blood-transmissible and 
transfusion-related disease.
1. Reduce excess mortality of poor
and marginalized populations:
by increasing access to safe blood,blood products,injections,
clinical and diagnostic technology and medical devices.
3. Developing
sustainable 
health systems:
by building sustainable management
capacity in the technologies involved in
blood and blood products,injections,as
fundamental components of sustainable
health systems.
BCT contribution in WHO’s four strategic directions2
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In achieving its strategic objectives,
BCT is acutely conscious of the need to
forge strong partnerships to ensure that
blood safety and clinical technology is
included in wider health and develop-
ment agendas. This includes such
major international initiatives that are
being steered by the department as the
Global Collaboration for Blood Safety,
the Safe Injection Global Network,
Regional Programmes for Quality
Management for Blood Transfusion
Services , all of which are described
later in this document.
Organization of the
BCT Department
The Department has four teams that
address the following health issue
areas: 
  Blood transfusion safety 
  Quality and safety of plasma
derivatives and other related
substances
  Safety of Injections
  Diagnostic imaging technology 
  Laboratory technology
  Clinical technology
  Medical devices.
There are several overarching
themes that may be identified through-
out the work of the department as a
whole. These include policy issues,
such as the promotion of sustainable
national programme, setting global
norms and standards for quality and
safety of blood products and related
biologicals, areas of research and
development and promotion of the
equity of access and use of blood,
blood products, injections, diagnostic
and clinical technology and medical
devices. Activities such as capacity
building and the facilitation of technolo-
gy transfer are included among the key
strategies.
Of the three departments in the HTP
cluster, the department of Blood Safety
and Clinical Technology is the smallest.
It has limited manpower and budgetary
resources, despite the very important
role that it has been assigned. In order
to meet the concerns of Member States
and carry out its responsibilities, the
department is seeking to strengthen
manpower where required, outsource
activities where it is cost efficient, and
seek extra-budgetary funds to carry out
agreed strategic activities.
Main areas of work
Blood Transfusion Safety 
The mission of the Blood Transfusion
Safety (BTS) team is to “promote the
formation of national blood programmes
which ensure the safety, quality and
adequacy of “blood and blood
components” to meet the needs of all
patients, transfused only when
necessary and are provided as part of a
sustainable blood programme within
the health care system”.
Blood safety activities should be
seen in the context of promoting
sustainable national blood programmes
which ensure the safety, quality and
adequacy of “blood and blood
components”, free from all transfusion
transmissible infections which include
among others: HIV, hepatitis B and C,
and Chagas disease.
Among the strategic activities of
BTS are to:
1. Strengthen “blood transfusion
services” with necessary guidelines
and national regulatory authorities
with necessary guidelines,
recommendations, training materials
and technical support in the areas of:
national policies and plans for
establishment of organized nationally
coordinated BT services, and
legislation/regulations. 
2. Promote blood donor
programmes based on voluntary non-
remunerated blood donors from low-
risk populations.
3. Promote the implementation of
quality management in blood
transfusion services.
4. Ensure the testing of all donated
blood for relevant transfusion
transmissible infections, blood3
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products using good manufactured
practices
5. Promote appropriate clinical use
of blood to prevent unnecessary
transfusions 
6. Improve the quality and safety of
blood transfusion services, especially
in developing countries 
7. Further develop the Global
Collaboration for Blood Safety (GCBS). 
The BTS team works in close
collaboration with other clusters such
as FHS/AIDS /child and adolescent
health (CAH), HIV/AIDS (HSI), Making
pregnancy safer, (HSI) and Nutrition
(CDS). 
Quality and Safety of Plasma
Derivatives and Other Related
Substances
Its mission is to “develop, establish and
promote WHO International Standards,
Guidelines and Technical
Recommendations to support
implementation of quality and safety
systems for the production and control
of blood products and related
biologicals. Main duties of the team
form an integral part of the WHO’s
normative functions in the area of
quality, safety and biological
standardization of blood products and
related biologicals, including
biotechnology products, used in the
prophylaxis, therapy or diagnosis of
human diseases. 
The strategic activities of QSD are to:
  Assess, apply and promote rele-
vant new technologies and meth-
ods for the standardization and
control of blood products and
related biologicals 
  Development of WHO Guidelines
and Recommendations for the
production and control of Blood
Products and Related Biologicals 
  Provide technical advice/assis-
tance on quality assurance and
safety of blood products and
related biologicals to National
Regulatory Authorities and their
Control Laboratories 
  Expert Committee on Biological
Standardization (ECBS), the WHO
Committee responsible for setting
global physical and written stan-
dards for biological substances
used in human medicine:
Subcommittee for Blood Products
and related Biologicals.
Safe Injection Global Network
(SIGN) Project
The Safe Injection Global Network
(SIGN) Project is an international coali-
tion of stakeholders that share a com-
mon interest in the safe and appropriate
use of injections. The SIGN coalition is
coordinated by a WHO secretariat
housed in the department of Blood
Safety and Clinical Technology. In addi-
tion to housing the SIGN secretariat,
BCT conducts its own activities for the
safe and appropriate use of injections. 
The strategic objectives of BCT for
the safe and appropriate use of injec-
tions worldwide include:
  Policy: To strengthen the capacity
of countries to formulate, imple-
ment, monitor, and update nation-
al policies for safe and appropri-
ate use of injections
  Quality and Safety: To ensure quali-
ty and safety of injection devices
  Access: To ensure equitable avail-
ability and affordability of injec-
tion devices
  Use: To promote appropriate,
rational, and cost-effective use of
injections and other percutaneous
or permucosal procedures per-
formed in medical and other
settings.
Diagnostic Imaging and
Laboratory Technology 
The Diagnostic Imaging and Laboratory
Technology (DIL) team plays an impor-
tant role in strengthening the quality of
performance of health laboratory servic-
es and imaging technology in countries,
with emphasis on the intermediate
level. It is comprised of a Diagnostic
Imaging group and a Laboratory
Technology group.4
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The mission of the Diagnostic
Imaging group is to “promote quality,
quantity, and equity of diagnostic imag-
ing services according to local needs”,
and its main strategic activities include:
  Preparing guidelines for effective
choices in diagnostic imaging
  Creating educational programmes
and learning material for appropri-
ate and adequate use and main-
tenance of diagnostic imaging
equipment and procedures
  Providing global guidance for
radiation protection in medicine
and global quality control of
radiotherapy installations.
The mission of the Laboratory
Technology group is to “promote and
advocate standards for establishing
appropriate medical diagnostic laborato-
ry services to ensure quality of health
care and prevention of diseases”, and
its strategic activities include:
  Global standardisation of labora-
tory procedures and reagents for
the diagnosis, prevention and
monitoring of disease 
  Development and implementation
of internal quality control and
external quality assessment pro-
cedures 
  Supporting countries by develop-
ing strategies for the improve-
ment of diagnostic laboratory
services, with emphasis on the
primary health care level 
  Facilitating transfer of appropriate
diagnostic laboratory technology
to countries in need through
capacity building and develop-
ment, assessment and distribu-
tion of information on technology.
Devices and Clinical
Technology 
The Devices and Clinical Technology
(DCT) team facilitates the transfer of
techniques and devices for the clinical
treatment of patients. The team is com-
prised of a group dealing with Devices
and one dealing with Clinical
Technology (District Surgical Services). 
The Clinical Technologies group has
the mission to “promote the quality of
clinical care through identification, pro-
motion and standardisation of proce-
dures, equipment and materials particu-
larly at first referral level (district hospi-
tal)”. Its main strategic activities include:
  The development of guidelines
on effective clinical procedures
particularly at the district level
(surgery, obstetrics, anaesthetics,
orthopaedics, etc.)
  To advocate and promote the
development and use of selected
appropriate innovative equipment
and materials (oxygen concentra-
tor, haemoglobin colour scale,
etc.) 
  To promote and facilitate the train-
ing of health care providers to
improve clinical care and support
capacity building.
The Devices group has the mission to
“advocate and provide technical sup-
port for appropriate health technology
to enable the expansion or develop-
ment of sustainable and cost-effective
health services”, and its strategic activi-
ties include:
  Supporting research and develop-
ment of appropriate technology
for health services for countries in
need 
  Strengthening capacity building,
improving the process of equip-
ment donations and technology
transfer in developing countries in
regard to the safety and efficacy
of devices (i.e., selection, use and
disposal of skin-piercing medical
devices to ensure safety)
  Supporting countries in the
application of health technology
for safe and efficient waste
management
  Strengthening countries capacity
to improve health care technolo-
gies management and mainte-
nance within a broad context of
health systems and services
development.5
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In order to perform some of these
DCT activities, we are collaborating
intensively with departments in other
clusters. Worthy of note are the inter-
cluster collaborations: BCT and the
Evidence and Information for Policy
cluster’s Organization of Health Services
Delivery (OSD) department for activities
on health technology management and
maintenance. Development of technical
guidelines and distance learning materi-
al will be part of the management and
maintenance project for developing
countries; and also child and adoles-
cent health (CAH), HIV/AIDS (HSI),
Emergency preparedness and response
(EHA), Making pregnancy safer (HSI),
(FHI) Diagnosis of Tuberculosis.
This activity will consider such
issues as: needs assessment (with the
assistance of a software based planning
and management tool called the
Essential Health care Technology
Package), spare parts, training, preven-
tive maintenance, repair of existing
equipment and guidelines on medical
equipment donations. Based on WHO’s
past experience on health technology
management, national projects will be
implemented or improved in selected
countries.
The second inter-cluster collabora-
tion is between BCT and the Sustainable
Development and Healthy Environments
cluster’s Protection of the Human
Environment (PHE) department, for activ-
ities on health care waste management.
The strategy relies on the following ele-
ments: Development of a database,
preparation of guidance material, avail-
ability of waste management options
and development of country plan.
Main activities
Each of the main activities of BCT are
described in the context of the BCT
Strategy in the next section, by primary
objective, overall target and giving the
critical indicators of performance. A fur-
ther chapter lists the principal special
initiatives currently being undertaken or
proposed.
The BCT Strategy hinges on four
key primary objectives: policy, quality
and safety, access, and use. These
terms have a particular significance to
the Strategy, and often a particular
meaning, and thus it is worth providing
a description and rationale for the
choice of these primary objectives.
Policy
An absence of policies based upon the
quality cycle – in which action plans are
formulated, implemented, evaluated,
and updated – limits the ability to
progress in blood and injection safety
as well as in diagnostic and clinical
technology. Thus our first objective is to
strengthen the capacity of countries to
formulate, implement, monitor, and
update national policies and plans for
blood, blood products, injections, diag-
nostic, clinical technologies, and med-
ical devices. This includes policies,
global collaborations, and global sys-
tems to monitor impact.
Quality and Safety
Blood products and technology can
only reach the quality and safety
required for their intended use if the
necessary guidelines and systems are
in place to optimise processes. In addi-
tion, appropriate controls must be
applied on the production and on the
product, as applicable. Thus, our objec-
tive is to assist countries in ensuring the
quality and safety of blood and blood
products and related substances, injec-
tions, diagnostic and clinical technolo-
gies, and medical devices. This
includes the development of norms,
standards, establishment of guidelines,
and international reference preparations;
research, development, and evaluation;
and national quality systems through
comprehensive training and creation of
networks and strengthening the techni-
cal expertise of national regulatory
authorities. 
Access
The global database on blood safety
indicates that 80% of the world’s6
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population does not have access to reli-
able and safe blood. Thus, a primary
objective of the BCT Strategy is to sup-
port countries in ensuring equitable
availability and affordability of blood,
blood products, injections, diagnostic,
clinical technologies, and medical
devices. This includes ensuring continu-
ous and sufficient quantities of appropri-
ate equipment, reagents and supplies,
and strengthening their capacity to pro-
duce basic supplies locally.
Use
Access to appropriate health technolo-
gy, including safe blood and safe injec-
tions, can only be ensured to the extent
that they are used appropriately and in
a reliable manner. Thus a primary objec-
tive is to promote the appropriate and
cost-effective use of blood, blood prod-
ucts, injections, diagnostic, clinical tech-
nologies, and medical devices. Use also
involves maintenance of equipment,
appropriate use of test kits and reagents
in order to produce reliable results. An
additional aspect is training and building
the necessary skills to correctly use the
available health technology.  ❒7
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T
he four primary objectives of the
Blood Safety and Clinical
Technology relate to policy,quality and
safety,access and use. In this chapter, the
relevant targets within each objective
are discussed. These are then illustrat-
ed by the main activities proposed for
2000-2003, their expected outcomes,
and the ways in which we aim to meas-
ure performance.
Advocacy for nationally coordinated blood
transfusionprogrammes
Blood transfusion services in countries are often
given low priority and many are still very poorly
organized.Government commitment and sup-
port for a well organized nationally coordinated
service is the first step to ensure sustainability,
and is a prerequisite to ensuring safe blood and
blood components.This commitment should
include financial support.
Thus,WHO aims to carry out a programme of
high-level advocacy with national governments,
ministries of health,ministries of finance and
ministries of education in respect of blood trans-
fusion services.Each country should make the
political and financial commitment to establish
and maintain a nationally coordinated blood
transfusion service.WHO will achieve this by pro-
ducing and distributing guidance materials on
developing national policies and plans,and by
holding workshops and undertaking personal
meetings with relevant government ministries
and health service officials.This activity also
relates in providing advocacy to the Ministry of
Health to ensure:
  Availability of adequate trained staff at all
level in BTS
  Economy of scale by centralising activities
  Development of costing procedures
  Regulation by competent national regulatory
authorities
  Development of ability to handle disaster
situations.
WHO can act as a adviser and provide technical
assistance for bilateral or multilateral financial
support;contact ministries to discuss restructur-
ing their blood programmes;organize a regional
workshop on national blood programmes,
including policies and plans;and expect to find
the restructuring of blood transfusion services in
progress in 2-3 countries.
The result of this programme will be a communi-
cation/advocacy/funding strategy on blood safe-
ty (to build on the World Health Day on Blood
Safety launched in 2000).
The success of this activity will be measured by
the number of countries that have shifted
towards a nationally coordinated blood transfu-
sion service,and the number of countries with an
appropriate financing system to ensure the sus-
tainability of the blood programme and an
improvement in the Safety Quality and adequacy
of Blood Supply.
The Blood Safety and
Clinical Technology
Strategy
Policy
Target 1: Formulation,implementation,monitoring,and updating of
national policies and plans8
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Strengthening diagnostic laboratories
through appropriate national policies
The majority of developing countries lack experi-
ence both in the creation of national policies for
health laboratory services,and in the manage-
ment of the national health laboratory services
network.As a result of the lack of national poli-
cies,countries have not ensured that laboratories
meet the minimal requirements needed in order
to provide authorities with information for dis-
ease surveillance and to support clinical services
in patient care effectively.
The objectives of WHO’s activities are thus to for-
mulate,implement and update national policies
and plans for clinical diagnostic laboratory servic-
es and technologies to meet requirements for
disease surveillance and patient care.We ? aim to
create a generic policy and plan (i.e.,standard-
ised items that should be included in national
policies) to enable well functioning laboratories
within the health structure.
Steps in the process include the staging of two
inter-country workshops to prepare plans of
action;organizing an informal consultation on
the role of public health laboratories;and assess-
ing the national laboratory network in four coun-
tries,and providing them with advice on appro-
priate strategies for the establishment of labora-
tory quality systems.
Clearly,the success of this activity will be meas-
ured by the number of countries with a national
policy,plans,for laboratory services;developed
and/or implemented.
Nationally coordinated use of appropriate
and safe diagnostic imaging services 
In at least one third of all patients,diagnostic
imaging is an absolute requirement for proper
diagnosis and treatment,and the need increases
as the life expectancy of the population is
improving.In several developing countries,such
services are either insufficient,or not at all avail-
able,and national coordination is often lacking.
The main reason for this is the lack of properly
trained staff.The salaries offered to properly
trained personnel in governmental institutions
are generally too low compared with those
offered by private institutions.We advocate that
staff at all levels receive proper training,and that
steps should be taken to avoid properly trained
staff members being tempted to leave govern-
mental institutions.
Working with ministries of health to discuss the
structure and future development of diagnostic
imaging services,and organize regional work-
shops on appropriate use of such services.
Among the indicators of performance will be the
number of countries with properly functioning
diagnostic imaging services,and the number of
countries with sufficiently trained staff.
Safe and appropriate use of injection
policies 
The aim of this activity is to strengthen the
capacity of countries to formulate,implement,
monitor and update national policies for safe and
appropriate use of injections.
Key areas of work include (1) advocacy for
national policies and plans for injection safety,(2)
global monitoring system for injection safety
(including estimation of the global burden of dis-
ease attributable to unsafe injection practices
and standardized tools to assess and evaluate
injection practices),and (3) maintenance of the
Secretariat of the Safe Injection Global Network
(see also the section on Key Initiatives below).
Figure 1: Regulation of the BTS
Policy/plan or legislation 37%
Policy/plan and legislation 37%
None 26%9
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Indicators of the performance of this activity
include (1) the number of countries with policies
and plans for safe and appropriate use of injec-
tions,(2) the availability of a Global Database on
Injection Practices and (3) the number of associ-
ates in the Safe Injection Global Network.
Advocacy for national policies and plans
for district surgical services
Many patients presenting at district hospitals
require surgical treatment for trauma,obstetric,
orthopaedic and abdominal emergencies,but
often surgery cannot be safely postponed to
allow the transfer of the patient to a secondary
or tertiary-level hospital.In many developing
countries,acute surgical and anaesthetic care in
district hospitals is provided by inadequately-
trained,non-specialist medical,nursing and para-
medical personnel,with limited facilities,equip-
ment and supplies.The poor organization and
inadequate resourcing of district surgical services
contributes to unacceptable rates of mortality
resulting from trauma,obstetric complications,
non-traumatic surgical disorders and disability
resulting from injury.
The objective of this activity is to improve stan-
dards of surgical and anaesthetic care at first-
referral level,particularly in general surgery,
anaesthesia,obstetrics and gynaecology,trauma-
tology,orthopaedics and rehabilitation.WHO will
provide advocacy to Ministries of Health to pro-
mote government commitment and support for
the development of effective district surgical
services,with adequate human and financial
resources.It will also promote the development
of policies and plans at both national and district
level to strengthen district surgical services,
including:
  Organization and management of district
surgical services
  Education programmes for all personnel
involved in surgical and anaesthetic care,in
conjunction with academic institutions and
professional bodies
  Upgrading,repair and maintenance of district
hospitals to required standards
  Appropriate physical facilities and clinical
support services for surgical,obstetric and
acute care 
  Appropriate equipment and instruments
  National systems for the supply of essential
drugs,surgical supplies and other consum-
ables required for common surgical and
obstetric emergencies
  National quality systems for surgical services,
including standards,clinical guidelines,stan-
dard operating procedures,records and audit.
The activity will include the preparation of guide-
lines and recommendations on the organization
and resourcing of essential surgical services at
first-referral level.This will be followed by region-
al workshops to promote the development of
national policies and plans for district surgical
services and continuing education for all person-
nel involved in acute surgical care.
Indicators for monitoring this activity will include
the number of countries that develop and imple-
ment national policies and plans to strengthen
district surgical services;the number of countries
that establish continuing education programmes
in acute surgical care;the number of countries
that establish systems to ensure adequate and
reliable supplies of drugs,surgical supplies and
other consumables;the number of countries that
establish national quality systems in surgical
services.
WHO will participate actively in world-wide net-
working through the Global Collaboration for
Blood Safety (GCBS) and the Safe Injection Global
Network (SIGN),both of which are described
among the key initiatives of the Strategy in
Chapter 3.Success in these endeavours is meas-
ured by the number of countries joining the col-
laborations as associates.
Policy
Target 2: Global collaborations10
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The principal activities undertaken in support of
this target are given below.In general,a range of
results is expected,including WHO recommenda-
tions and guidelines for the quality and safety of
blood,blood products,and related substances,
WHO biological reference preparations for blood
products,related substances,WHO reference doc-
uments on diagnostic imaging and laboratory
diagnostics,international standards on medical
devices,the harmonisation of medical devices
regulations,and strengthen national regulatory
authorities for devices and biologicals.
These are measured by reviewing the number of
countries implementing WHO recommendations
and guidelines on quality and safety of blood,
blood products,and related substances,the num-
ber of institutions with improved efficiency and
quality of diagnostic imaging and laboratory
services,the number of standards and WHO
international biological reference preparations
developed and used,and the number of coun-
tries implementing regulations on medical
devices and biologicals based upon international
standards.
International Biological Reference
Materials for Blood Products and Related
Biologicals
This activity aims to develop,establish,and pro-
mote international biological reference materials
(physical standards) which form the basis for
global comparability of biological activities in
blood products and related biologicals used in
prophylaxis,therapy and diagnosis of human dis-
eases.The production of these materials involves
considerable international collaboration and
coordination of laboratory work,in both devel-
oped and developing countries as appropriate,
Global Database on Blood Safety 
Information on blood and blood products safety
and on blood transfusion services in countries
and regions needs to be collected and analysed
in order to assess needs,formulate strategies,
plan,implement and evaluate activities,and con-
duct research and assist the various bilateral and
multilateral agencies to coordinate and effective-
ly implement support projects.The objective of
this activity is to collect and analyse data from all
countries on blood and blood product safety as
the basis for effective action to improve safe
blood transfusion capabilities globally
Questionnaires on blood and blood products
safety and on blood transfusion services have
been developed and are being sent out
bi-annually.Based on the replies received,the
questions have been refined in order to enhance
the scope of data collection.Questionnaires are
being translated into the main WHO languages
and additional background information will be
provided to facilitate the completion of the ques-
tionnaire.Data are analysed per region and glob-
ally;a summary of the findings are made avail-
able through the WHO web-site,and printed
reports are issued bi-annually.
Among the expected outcomes of this activity
are a global database for blood safety and a
global database for injection practices (with
annual updates).Indicators to measure perform-
ance include the number of countries for which
complete information required for progress
indicators is available.
Policy
Target 3: Global systems to monitor impact
Quality and Safety 
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guidelines and reference materials11
WHO
Blood Safety and
Clinical Technology: 
2000–2003 Strategy 
through WHO international collaborative studies,
the results of which are considered by the Expert
Committee on Biological Standardization,and if
acceptable established.The following activities
are included under this item:
  Biological Standardization in thrombosis and
haemostasis
  International Biological Standards for in vitro
diagnostic procedures
  Review and update of the WHO International
Standards for Blood Grouping Reagents
  WHO Reference Preparations for Diagnostic
Kits used for the detection of HBsAg,anti-HCV
and anti-HIV antibodies
  Standardization of Nucleic Acid Amplification
Techniques (NAT) for virological safety testing
  WHO Biologicals web site:a catalogue of WHO
international biological reference prepara-
tions established by the WHO Expert
Committee on Biological Standards is pub-
lished via Internet at the following address:
http://www.who.int/technology/biological.ht
ml.This Catalogue is updated annually to
include the new adoptions and discontinua-
tions of materials by the Expert Committee.At
the request of the Expert Committee,web
hyperlinks will be developed with available
web sites of the WHO International
Laboratories for Biological Standards,national
regulatory authorities and relevant interna-
tional pharmacopoeias.A database for nation-
al biologicals regulatory control laboratories is
also under development so that we can
assure the widest promotion of WHO guide-
lines and technical recommendations and
international reference materials world-wide.
WHO guidelines and recommendations for
the production and control of blood
products and related biologicals
WHO recommendations and guidelines on the
production and quality control of biological
products,including blood products,constitute an
authoritative guidance for national regulatory
authorities and for manufacturers.The nature of
blood products and related substances raises
complex issues surrounding standardization,
quality control and safety,which require coordi-
nated research and consideration on an interna-
tional level.In practice,WHO standards,guide-
lines and recommendations serve as advice to
Member States for incorporation in to guidance
documents and form the basis of national stan-
dards and technical regulations.The norms and
standards established by WHO form the basis for
harmonization of biological products world-wide.
Among the indicators measuring the perform-
ance of this activity are:the increase in the level
of harmonization on regulation between coun-
tries;the number of countries implementing reg-
ulatory programmes for the evaluation and con-
trol of blood products and related biologicals
according to WHO Guidelines and recommenda-
tions.The following activities are included under
this item:
  Guidelines on viral inactivation/removal pro-
cedures for plasma and plasma derivatives 
  Guidelines for the control and standardization
of Factor VIII and Factor IX biological meas-
urements
  Guidelines on technical issues regarding plas-
ma contract fractionation
  Guidelines for the collection of plasma for
manufacture of plasma derived products.
International Standards and Reference Reagents
Biological
Substances12
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Expert Committee on Biological
Standardization  
The programme for developing WHO internation-
al biological reference materials,guidelines and
recommendations for blood products and relat-
ed biologicals is approved by the WHO Expert
Committee on Biological Standardization.The
WHO Expert Committee on Biological
Standardization is supported and assisted by the
interdepartmental biologicals cross-cutting quali-
ty assurance group,located in the departments
of Vaccines and Biologicals and Blood Safety and
Clinical Technology.A subcommittee structure
specific to the areas covered by the Committee,
including blood products and related biologicals,
aims to ensure best interactions with national
regulatory authorities and systematic consensus
building regarding international standards,
guidelines and recommendations.
This activity aims at 1) ensuring the adoption of
guidelines on the quality assurance of blood
products and related substances,2) the establish-
ment of WHO international biological reference
preparations,3) providing guidance for the
preparation,characterization and establishment
of international and other standards and refer-
ence reagents for biological substances,4) sup-
porting regulatory research to ensure quality and
safety of plasma and plasma derived products,
and 5) technical coordination with medicines
control authorities,pharmacopoeias,WHO labo-
ratories for biological standards and
Collaborating Centres,NGOs,international scien-
tific societies,manufacturers associations and
other interested parties.
Harmonization on the regulation of
medical devices  
The regulation of medical devices is an increas-
ingly important component of health care that is
growing in complexity.At a time when developed
countries have installed quality systems and qual-
ity control,only a few developing countries have
functional systems to regulate imported or locally
manufactured medical devices (which would
assure their safety and effectiveness),or the tech-
nical capacity to implement these.
The objective of this activity is to cooperate with
WHO regions for the development of regional
projects in the area of medical device regulation.
This would include joint activities with the Global
Harmonization Task Force (GHTF),a multinational
consortium formed in 1992,and its study groups
to unify international regulatory requirements.
WHO would encourage more countries to join
the Task Force,in order to benefit from the expe-
riences of its participant nations and avoid the
further proliferation of disparate regulatory
regimes for medical devices.
The specific activities include:the translation and
circulation of the existing documents (the revised
FDA Model program for medical devices:an
international guide,and the Guideline for the
development of medical device regulation pre-
pared for PAHO) for comments;the revision of
the existing documents and the development of
a new draft on medical device regulation to
come with our WHO guideline by 2002;the par-
ticipation at the GHTF conferences and contribu-
tion to the work of study group 2 on vigilance
and post market surveillance (devices problem,
recalls,and alerts to the global community).
Regional workshops on the regulation of medical
devices will be staged.We will promote and iden-
tify information sources for medical devices regu-
lation,establish a uniform format to certify that
product exported by countries comply with their
domestic regulatory requirements.
Among the indicators measuring the perform-
ance of this activity are:the increase in the level
of harmonization on regulation of medical
devices between countries;the number of coun-
tries implementing regulatory programs for med-
ical devices according to WHO guidelines and
recommendations;the number of countries with
national external medical devices quality assess-
ment schemes increased.
Quality and safety of injection devices 
Quality and safety of medical devices starts with
good quality systems and controls during the devel-
opment and manufacturing phase of the device.
This aim of this activity is to ensure the quality
and safety of injection devices by working in
close relation with the industry on the organiza-
tion of clinical trials for evidence based decision
on recommendation for new technology and
improvement of the existing one.13
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Key areas of work include (1) providing safer
injection device by carrying our field evaluations
of newer,safer injection devices and (2) establish-
ing an international vigilance system for injection
devices.
Indicators of the performance of this activity
include (1) the number of appropriate new
devices and equipment that have been evaluated
and (2) the existence of an operational system to
control the quality of injection devices.
Establishing norms and standards for
medical devices 
Norms and standards are essential tools to
ensure the quality and safety of medical devices.
An important part of this activity will be to pro-
vide coordination for the better control of the
application of international norms and standards.
Ensuring the greater participation of all the
stakeholders will be our major objective.The
International Organization for Standardization
(ISO),and federation of national standards bod-
ies,will be assisted by WHO to build more
bridges for a better medical devices standardiza-
tion throughout the world.
To achieve this WHO will Establish or reinforce
liaison status with ISO and provide comments
on the work of some ISO technical committees
(TC 84,TC 210,….),for the better control of the
application of international norms and stan-
dards and finally to ensure a greater participa-
tion of all the stakeholders.The development of
norms and standards will be a join activity
between medical device manufacturers,regula-
tors,users of the medical device,the Global
Harmonization Task Force (GHTF) and ISO.Our
activity will focus on some target groups as the
autodisable (AD) syringe manufacturers to
begin the process of drawing up norms and
standards on AD syringes for therapeutic appli-
cations,as a contribution to the injection safety
project.An aide-memoire on medical device
quality and safety will be prepared.
The success of this activity will be measured by
the number of national regulations referring to
norms and standards;the availability of interna-
tional standard for AD syringes;the number of
syringe manufacturers producing safe syringes
according to international standards.
Among the principal results of the activities
aimed at achieving this target are:1) internation-
al reference preparation for new technologies for
the diagnosis of infectious agents representing
an emerging threats to blood safety (e.g.,trans-
missible spongiform encephalitis),2) the evalua-
tion of reagents,procedures,and equipment for
laboratory services,including new tests for trans-
fusion-transmitted infections,3) the evaluation
and post market surveillance for new medical
devices,including syringes supporting safer use
of injections,4) the evaluation of new waste dis-
posal options,and 5) collaboration with partners
for the development of equipment,including
equipment related to safe processing of blood.
Specific activities are given below.
Evaluation of HIV test kits
Blood transfusion saves millions of lives but is
unfortunately also an efficient route of transmis-
sion of HIV and other transfusion transmissible
infections (TTIs).Today,a new generation of test
kits for HIV are available (which are,for example,
able to detect simultaneously HIV antigen and
HIV antibody),enabling the early detection of
infection.This is a crucial line of defence in blood
safety.Increasing numbers of HIV test kits are
produced in developing countries,requiring an
independent organization such as WHO to assess
Quality and Safety
Target 5: Research,development,and evaluation of new technologies
and methods their quality.Data on locally produced test kits
are lacking.The capacity of test kits to detect dif-
ferent variants and strains is not uniform.
Therefore our evaluations are performed on
panels of more than 1000 well characterized
specimens from diverse geographical origins.
This activity,which is carried out with our WHO
Collaborating Centre in Antwerp,is thus aimed at
providing Member States,UN agencies and other
partners with technical information and advice
on the quality of HIV test kits,in order to enable
them to select screening tests most appropriate
for HIV testing strategies in different settings.
Specific activities include:the preparation,publi-
cation and wide distribution of an evaluation
report on the operational characteristics of HIV
test kits;the initiation of evaluations of HIV
Ag/Ab tests,ongoing evaluation of new HIV
ELISA tests,including local produced kits,and the
publication of a report on these activities,cover-
ing operational characteristics.
Evaluation of saliva and whole blood tests
for HIV
Saliva and whole blood tests are among the new,
simple HIV tests used in prevention and care
interventions for HIV/AIDS.This activity seeks to
improve these testing technologies by evaluating
their operational characteristics and comparing
their intrinsic accuracy with current standards.
We will facilitate and increase access to informa-
tion on the quality of simple HIV tests based on
new technology (serum,whole blood and saliva),
and define their appropriateness for particular
settings – for example blood transfusion centres,
antenatal clinics,voluntary testing and coun-
selling settings.The evaluations will be carried
out in field sites in different WHO regions.Among
the indicators used to measure the performance
of this activity are:the increased accessibility of
WHO/UNAIDS information and technical guide-
lines for HIV testing;independent data to enable
rational selection of the most appropriate whole
blood and/or saliva HIV tests in different settings;
improved HIV testing in antenatal clinics,volun-
tary testing and counselling centres;the number
of saliva assays evaluated;the number of whole
blood tests evaluated;reports published;updated
recommendations issued.
Evaluation of test kits for the detection of
hepatitis B and hepatitis C
It has been determined that,world-wide,17 % of
all blood donations are not reliably tested for
transfusion transmissible infections (TTIs).This
number increases to 43% if we consider only the
non-industrialised countries.Very few non-indus-
trialised countries test all blood donations for
either hepatitis B or C infection on a continuous
basis.Existing test kits are often inappropriate for
situations in developing countries and test kits
are often not affordable due to exorbitant prices
(particularly for hepatitis C).Recently new,appro-
priate technology has become available for the
detection of hepatitis B and hepatitis C infection,
some of which are produced in developing coun-
tries.However,comparative data on these new
test kits are lacking.
The capacity of test kits to detect different vari-
ants and strains is not uniform.Therefore our
evaluations are performed on panels of well-
characterised specimens (over 1,800 specimens)
from diverse geographical origins,including sero-
conversion and low titre performance panels.
Quality assessment of test kits are performed at
the WHO Collaborating Centre in London and at
various field sites in the different WHO regions.
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Figure 3: Blood safety
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Our aims are therefore to provide Member States
and agencies with technical information and
advice on the quality of test kits,so as to enable
them to select screening tests most appropriate
for their particular needs,and to develop appro-
priate testing strategies for hepatitis B and
hepatitis C infection.
The indicators for this activity include the num-
ber of high quality hepatitis C rapid tests identi-
fied,the number of high quality hepatitis C EIA
tests identified,the number of high quality hepa-
titis BsAg S/R tests identified,and the number of
high quality hepatitis BsAg EIA tests identified.
Appropriate testing technologies and
strategies for Chagas Disease
In geographical areas where Chagas Disease is
endemic,all blood donations should be screened
for infection with Trypanosoma Cruzi (T.cruzi).
Although T.cruzi infection is most important in
Latin America,other countries (USA,Europe) are
considering testing all blood donations for T.
cruzi due to migrant populations and increased
tourism.Available test kits,of which most are pro-
duced in Latin America,will be evaluated and
guidelines and appropriate and reliable testing
strategies will be developed.Discussions with
industry will be held to improve current technol-
ogy.Partnerships include the WHO Collaborating
Centre in Sao Paulo,as well as the University of
Iowa and international experts.
Indicators include number of test kits evaluated
and evaluation reports distributed.
Biological reference preparations for the
development of diagnostic tests for trans-
missible spongiform encephalopathies
This activity envisages creating a WHO repository
to facilitate the development of improved diag-
nostic tests for transmissible spongiform
encephalopathies (TSEs) based on available
research methods.Internationally agreed-upon
biological reference materials (BRMs) will be used
for the assessment and validation of assay sys-
tems to be applied in diagnostic procedures of
TSEs and for a global harmonization in evaluating
process validation data (clearance of TSE agents
from biological products).
The specific activities include the identification of
priorities for development of BRMs relevant to
public health,the development of a WHO reposi-
tory for positive and control materials derived
from humans and animals with TSEs (selection
and characterization of appropriate candidate
materials,development of protocols for WHO
Collaborative studies),the development of inter-
nationally agreed-upon parameters for classifica-
tion of human TSEs (harmonization of procedures
and reagents used for the classification and
nomenclature of PrPSc typing in human TSE
cases),the consideration of issues concerning the
appropriate uses of the BRMs,and follow-up of
scientific developments with potential public
health impact in the field.
Quality assurance of plasma-derived
medicinal products and plasma
fractionation activities
WHO has long recognized the importance of
capacity-building and improving the perform-
ance of national regulatory authorities and manu-
facturers in meeting appropriate international
standards.Considerable effort is planned for
strengthening developing country regulatory
activities in the area of plasma-derived medicines,
the goal being to upgrade their technical expert-
ise for the evaluation,control and national stan-
dards setting so that all plasma derivatives used
would be of assured good quality and safety.
This activity aims at preventing the transmission
of blood-borne viral diseases via plasma
Quality and Safety
Target 6: Development and implementation of national quality 
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products,upgrading the expertise of national
control authorities and laboratories in quality
assurance of plasma derived products,promoting
closer regional collaborative links among nation-
al control authorities,and facilitating the transfer
of information and technology.
The activity will be carried out in collaboration
with the WHO Regional Advisers at the Regional
Offices and upon the request of the countries.
Partners in the project will form part of a Task
Force,including WHO Collaborating Centres,
experts in the quality assurance of plasma prod-
ucts and plasma fractionation (from national con-
trol authorities and industry or other institu-
tions);international scientific societies;
Pharmaceutical Inspection Co-operation Scheme
(PIC/S),and the Expert Committee on Biological
Standardization.
Specific tasks include setting up the Task Force
on Quality Assurance of Plasma Derived
Medicinal Products,multi-country and regional
seminars and workshops (on quality and safety of
plasma for fractionation,strategies to meet the
requirements for producing safe plasma prod-
ucts,viral inactivation or removal procedures and
their validation,control tools to assure quality
and safety in plasma products),the development
of guidelines on viral inactivation or removal pro-
cedures and validation that are established by
the Expert Committee on Biological
Standardization.
Increased safety and quality of radiotherapy
Radiotherapy is increasingly being used world-
wide for curative as well as palliative treatment of
malignant diseases.Especially in poor,develop-
ing countries without proper access to modern
oncological treatment,radiotherapy often is the
only treatment available for such patients.
However,the lack of sufficient trained personnel
and the absence of proper maintenance and cali-
bration of equipment may reduce the effect of
radiotherapy,or cause severe and life-threatening
side-effects to the patients..
Therefore,our main objective is to have as many
radiotherapy installations as possible included in
the WHO/IAEA quality assurance programme.
Specifically,we will start by having at least one
radiotherapy institution in each of the African
countries included,eventually extending this to
include all countries in the former Soviet Union.
We will develop a complete knowledge base on
radiotherapy installations in the African Region
(to be collected together with the African
Regional Office) and in the former Soviet Union
(to be collected together with the European
Regional Office).
Among the indicators will be the number of
radiotherapy institutions included in the
WHO/IAEA quality assurance programme,and
the number of radiotherapy institutions with
improved quality and safety.
Access 
Target 7: Continuous and sufficient quantities of appropriate
equipment and supplies
WHO bulk procurement of test kits for HIV,
hepatitis B and hepatitis C
The risk of transfusion transmissible infections
(TTIs) can be substantially reduced by screening
for all main TTI’s,HIV,hepatitis B and hepatitis C.
Although a large number of screening tests with
varying characteristics have been developed,the
cost of these test kits is often prohibitive 
for many developing countries.Countries and UN
organizations can make considerable savings
through the bulk procurement of test kits.In
1999,for example,the total savings on all HIV test
kits purchased amounted to US$ 2.7 million.This17
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means that funds are freed to buy an increased
number of test kits,or can be used to cover other
indispensable purchases.
The main activity proposed is (in collaboration
with WHO’s procurement services,other interest-
ed parties in WHO,and UNAIDS) to promote and
negotiate the availability of high quality HIV,hepa-
titis B and hepatitis C test kits at a reasonable cost.
Based on an updated selection of high-quality
HIV test kits (ELISAs,simple/rapid and confirma-
tion tests),a new tender will be organized for bulk
procurement of HIV test kits,and develop and
publish an information booklet on the bulk pro-
curement programme for UN agencies,govern-
ments,national AIDS programmes,and NGOs.We
will also select and organize a tender for bulk pro-
curement of hepatitis B and hepatitis C test kits.
Among the indicators that can be used to moni-
tor this activity are the number of test kits pur-
chased in each category ,and the cost savings as
compared to the market (catalogue) prices,
analysed by regions.
Access to technology for laboratory
diagnostics
With a view to supporting countries in ensuring
equitable availability and affordability of diag-
nostic laboratory technology,this activity aims at
strengthening the capacity to produce laborato-
ry diagnostic materials locally.Workshops on
local production of diagnostic laboratory materi-
als organised in at least two Regions.The activity
will be assessed in terms of the number of coun-
tries with local capability to produce laboratory
reagents.
Minimum requirements for district surgical
services
District hospitals in developing countries per-
form a wide range of surgical procedures,often
with inadequately trained,non-specialist staff,
poor facilities and limited,low-technology appa-
ratus and equipment.
WHO will promote the provision of safe surgical
and anaesthetic care through:
  Development of recommendations on mini-
mum requirements for district surgical services
  Assistance to national health authorities in
the development of national lists of essential
equipment and supplies required at first-
referral level
  Advocacy to promote the development and
use of appropriate innovative equipment and
materials 
  Feasibility study on the bulk purchasing of
essential surgical and anaesthetic equipment
and instruments (oxygen concentrator).
Figure 4: HIV diagnostics – HIV bulk purchase 1989-1999
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Promotion of blood donor programmes
based on voluntary non-remunerated
blood donors 
Although regular,voluntary,non-remunerated
blood donors from low-risk populations are con-
sidered as the safest donors,blood donation sys-
tems in many developing countries are still
dependent predominantly on replacement/fami-
ly/paid donors.There is lack of properly organ-
ized blood donor programmes in most of the
developing countries.Similarly,there is no data-
base of regular blood donors and only a very
small fraction of voluntary donors are regular
blood donors.Most of the blood transfusion
centres do not have trained donor recruiters.
There is a great need for advocacy and providing
technical support for developing national blood
donor programmes.The activities aim at devel-
oping and/or strengthening the national blood
donor programmes in WHO Member States
based on voluntary,non-remunerated blood
donors from low-risk populations,depending on
the local situation,requirements and available
work force.This includes organization of training
workshops at country level for training of blood
donor organisers,donor recruiters and blood
transfusion personnel involved in donor recruit-
ment and retention activities.
Indicators to monitor and evaluate the outcome
of this activity include increase in total number of
voluntary,non-remunerated donors,number of
staff trained in donor recruitment,reduction in
number of paid donors and reduction in preva-
lence of transfusion transmissible infections
among blood donors.
Safe blood collection systems and
component production 
Procedures for safe and effective blood collection
are required to reduce the risk of bacterial con-
tamination of donated blood and to ensure the
quality and efficacy of blood components pre-
pared from the donated blood unit.
The activity aims at developing learning materi-
als on safe and effective blood collection and
production of quality blood components.The
learning materials will be developed in two phas-
es.They will be developed as a supplement to
the existing distance learning materials on “Safe
Blood and Blood Products”and will promote the
use of standardized procedures for safe blood
collection and,ultimately,the production of high-
quality blood and blood components.
Indicators to evaluate the utilization of learning
material include a decrease in the number of
Use
Target 8: Appropriate collection,processing,and clinical use of
blood and blood products
Ensuring equitable availability and
affordability of injection devices
This aim of this activity is to ensure equitable
availability and affordability of injection devices.
Key areas of work include (1) decision-making
guide for the choice of injection devices,(2)
guidelines on financing of injection devices for
countries and donors,(3) bundling financing plan
for injection devices,and (4) technology transfer
for the production of safer injection devices.
Indicators of the performance of this activity
include (1) the number of countries using the
guidelines to make choices of injection devices,
(2) the number of countries increasing the avail-
ability of injection devices,(3) the number of
donors adopting the “bundling”policy statement
and (4) the set-up of local production of safer
injection devices.19
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discarded blood units due to inappropriate
blood collection,a reduction in the rate of bacte-
rial contamination of blood components,
improved traceability of plasma and serum used
for processing,improvements in the quality and
efficacy of blood components and in the quality
of plasma for processing and fractionation.This
will lead to greater safety and efficacy of blood
products and also minimizing the risk to both
donors and recipients.
Distance learning programme for safe
blood and blood products (DLP)
Blood transfusion staff,especially those in small
hospital blood banks in developing countries,
often lack opportunities for further training and
to participate in refresher courses.Distance learn-
ing offers a flexible,cost-effective way of provid-
ing training in blood safety for larger numbers of
staff,at lower cost and with less disruption to
services than is possible with conventional cours-
es.In promoting the use of distance learning in
transfusion medicine,WHO/BTS has published
five modules of learning materials,Safe Blood
and Blood Products,for staff with responsibility
for donor recruitment and for the collection,pro-
cessing and issue of blood for transfusion.It has
also trained senior blood transfusion service per-
sonnel from over 100 countries in establishing
distance learning programmes (DLP) in blood
safety supported by the learning materials enti-
tled Establishing a Distance Learning Programme
in Blood Safety:A Guide for Programme
Coordinators.This activity aims at increasing the
quality and coverage of training for blood trans-
fusion service staff within the workplace as part
of the process of improving the quality and safety
of national blood supplies.
English,French,Spanish,Chinese,Russian and
Portuguese editions of the modules are now
available.An Arabic edition is being produced
and several countries are translating the modules
into their national languages.
Priorities for the future development of the dis-
tance learning programme include the evalua-
tion of successful national distance learning pro-
grammes and technical support to countries that
plan to start programmes,notably China and
India.
Clinical use of blood
A large proportion of transfusions are given inap-
propriately.The appropriate clinical use of blood
is critical,particularly in areas with a high preva-
lence of transfusion transmissible infections and
in areas where there is a shortage of blood units
and resources for health are limited.The objec-
tive of this activity is to develop and promote
good transfusion practice to ensure that the right
patient receives the right blood for safe adminis-
tration at the bed side,as well as the right reason,
in accordance with national guidelines on the
clinical use of blood.This will be achieved
through the dissemination of WHO learning
materials as well as training of prescribers of
blood and blood products (nurses,surgeons and
anaesthetists and others).
Regional workshops using the clinical use of
blood learning materials (English version) have
been organized.Learning materials are being
translated into French and Spanish,Chinese,
Russian,Arabic and other languages.
Haemoglobin Colour Scale 
The Haemoglobin Colour Scale was developed by
WHO as a simple,accurate,and cost effective clin-
ical device for the detection and management of
anaemia for use in areas where laboratory facili-
ties are not readily available,and for haemoglo-
bin surveys to identify populations at risk.
It was developed in response to such situations
and will be important in a variety of areas includ-
ing blood donations,primary health care,antena-
tal,paediatric and trauma care.The Scale would
be invaluable in peripheral health services,espe-
cially in developing countries,and in the screen-
ing of blood donors.It is ideal for determining
blood donor suitability,particularly as a replace-
ment for the copper sulphate specific gravity (SG)
method).
WHO has evaluated the device extensively in lab-
oratory and field conditions.Over the past four
years,the field evaluations were carried out in all
six WHO regions,in developed and developing
countries,in blood transfusion services,antenatal
clinics,primary health care settings,and nutri-
tional survey/research studies.The results of20
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these trials have led to minor modifications in
the instructions to ensure correct use.
After the production of several batches of the
Scale we now have achieved the required quality
in the printing of the colours in the Scale.Limited
quantity of the WHO Haemoglobin Colour Scale
has been allocated to selected sites in all regions.
The objective is to transfer the production,mar-
keting,logistic for distribution and sales to a
commercial partner ready to finance the initial
cost to bring the product to the market.A licence
Agreement has been signed with a German com-
pany,COPACK.
The work will include:the control of the manu-
facturer activity in accordance with the licence
agreement signed for the production and distri-
bution of the scale,the coordination of the vali-
dation of the scale by a WHO collaborating cen-
tre;the identification of new donors to facilitate
the access to the device;the development of flier
and other information tools;development of the
HbCS starter kit;the largest dissemination of the
scale to the public sector will still require work
with the manufacturer and development of tools
for promotion and training.
A second generation of the Haemoglobin Colour
Scale will be developed and other non-invasive
haemoglobin monitoring technologies will also
be investigated to help detecting anaemia,par-
ticularly of pregnant women.
The starter kit will be first available in English and
French;other language editions of the Scale will
be prepared to respond to the worldwide needs.
Monitoring and evaluation will be provided by
the number of countries currently using the scale
as a screening tool for blood donors and other
application;the increase in anaemia detection
programmes using the scale;The quantity of the
haemoglobin colour scale produced and distrib-
uted by the manufacturer.
Among the expected outcomes related to this
target are 1) Regional external quality assess-
ment schemes (EQAS) for transfusion-transmissi-
ble infections,immuno-haematology,and select-
ed laboratory disciplines,2) educational material
and training programmes on use and mainte-
nance of diagnostic imaging facilities and equip-
ment,3) guidelines for the use and cost-effective
strategies for laboratory methods and diagnosis
of transfusion-transmitted infections,and 4)
guidelines for good diagnostic practices.
The associated critical indicators include 1) The
number of countries participating in External
Quality Assessment Schemes (EQAS) for transfu-
sion-transmissible infections,immuno-haematol-
ogy,and other laboratory disciplines,2) the num-
ber of countries with improved,safe,and appro-
priate imaging services,3) the number of coun-
tries with established standard operating proce-
dures in laboratory services,and 4) the number
of countries implementing good diagnostic
practices.
Regional external quality assessment
schemes for transfusion transmissible
infections (HIV hepatitis B and hepatitis C) 
There are many steps and procedures required
between blood being drawn from the donor and
the patient receiving the transfusion.An ade-
quate quality system should be in place to moni-
tor each step.In many countries there is a need
and demand for technical guidance and didactic
material on how to implement a quality system.
The principal objective of this activity is thus to
promote the concept of quality systems and to
assist blood transfusion services and national
authorities in implementing quality systems,
including quality assurance,quality control,stan-
dard operating procedures and external quality
assessment for testing and safe blood supply.
Use
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Regional external quality assessment schemes
(REQAS) for transfusion transmissible infections
will be established covering four WHO regions:
two in Africa (one for anglophone countries and
one for francophone countries) and for South-
East Asia and the Western Pacific.
Partners include the CPHLS,London;NRLs,
Melbourne;Hopital Le Dantec,Dakar,and NBTS,
Harare.
A Newsletter discussing issues related to quality
assurance and quality management will be dis-
tributed to participants of the scheme.
As indicators to measure the performance of
these activities we may use the number of coun-
tries participating in regional EQAS for the main
TTIs,the number of countries of newly imple-
mented or improved quality systems,the number
of countries with a NEQAS.
Development of Regional External Quality
Assessment Schemes (REQAS) in Blood
Group Serology 
Adequate testing of all donated blood units in
blood group serology is an important strategy for
ensuring safe blood transfusion.Quality manage-
ment in blood transfusion laboratory has
attained a greater significance in view of the risks
associated with blood transfusion due to poor
quality.Establishment of External Quality
Assessment Scheme (EQAS) is required to ensure
quality testing in blood group serology for all
donated blood units.
The activity aims at assisting WHO Member
States in promoting the concept of quality sys-
tems and in implementing national quality sys-
tems.Activities include organizing regional EQAS
in Blood Group Serology,conducting regional
training workshops,identifying areas for further
training and providing support in the areas of
need.Regional external quality assessment
schemes in Blood Group Serology will be estab-
lished covering four WHO regions:two in Africa
(one for anglophone countries and one for fran-
cophone countries) and for South-East Asia and
the Western Pacific.
Indicators to measure the performance of these
activities include development of WHO guide-
lines for organizing a National EQAS,number of
countries participating in regional EQAS in Blood
Group Serology,number of training workshops
and educational activities carried out during the
specified period and number of personnel
trained in concept of Quality Assurance and
External Quality Assessment.
Establishing regional training centres for
quality management 
These will be discussed below (under Key Issues)
in detail.
Appropriate,rational and cost effective use
of injections
This aim of this activity is to ensure appropriate,
rational and cost effective use of injections and
injection devices.
Key areas of work include (1) pilot projects in
each WHO region,(2) injection safety standards,
(3) guidelines for universal precautions,(4) tool-
box for behaviour change and implementation.
Indicators of the performance of this activity
include (1) availability of evaluation for pilot proj-
ects,(2) availability of injection safety standards,
(3) availability of universal precautions guide-
lines,and (4) the availability of a behaviour
change and implementation toolbox.
Use
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Improving blood safety by ensuring
reliable and appropriate HIV testing 
In many non-industrialized countries,HIV trans-
mission through blood is still occurring.
Assistance will be given to countries to develop
and implement national HIV testing policies,pro-
vide updated operational guidelines on appropri-
ate and reliable testing for HIV and training of
staff.Educational material will be made available
for training staff on these concepts.
The specific objectives are to assist and encour-
age countries to develop and implement national
testing strategies to ensure safe blood,and to
provide technical advice and training on opera-
tional aspects of reliable testing of HIV and other
TTIs.The content of the advice will cover princi-
ples of screening assays,selection of assays and
automated systems and good laboratory practice.
We will produce an educational set (document
and slides) on principles of screening assays,
selection of appropriate assays,and on quality
systems in BTS.After a workshop and field test-
ing,we will produce these educational materials
in English,French,Spanish and Russian.Follow-up
actions will include assessment visits,and further
intercountry workshops.
Blood cold chain
An effective blood cold chain (BCC) from dona-
tion to transfusion is an essential part of a nation-
al blood transfusion service if it is to ensure safe
blood for the patient.
Thus DCT aims to carry a programme:to deter-
mine the specifications of selected blood cold
chain equipment;to perform laboratory and field
evaluation of devices and indicators for the safe
storage of blood or blood product in all environ-
ments;to inform and educate users of cold chain
equipment on specifications of appropriate
equipment and devices for use in the mainte-
nance of the blood cold chain by producing a
publication with specifications for BCC equipment
and devices and by developing learning materials
for the maintenance of the blood cold chain .
The result of this programme will be:the estab-
lishment of WHO specifications for selected BCC
equipment;the development of protocols for
laboratory and field evaluations;the production
of reports on the laboratory evaluations done on
CFC-free refrigeration equipment for BCC,and on
blood time temperature indicators,by specialized
testing centres.Accordingly,we will produce a
publication with specifications for BCC equip-
ment and devices evaluated in the laboratory
and in the field,and will develop learning materi-
als for the maintenance of the blood cold chain.
Additional essential equipment for the blood
cold chain has been identified (e.g.,plasma shock
freezers,platelet agitators),laboratory and field
evaluations will be conducted and appropriate
specifications will be determined in order to
expand the range of equipment and devices nec-
essary to further improve the blood cold chain:
The work will also include:the collection of BCC
equipment and material for the preparation of a
product information sheet book;the field evalua-
tion and final editing of learning material;the
development of a specific project with a Swiss
school of engineers on the management of the
logistics of the blood cold chain.
Longer-term activities include the production of
a practical manual on the management of blood
inventory,the establishment of minimal stan-
dards for blood cold rooms,concept develop-
ment of a mobile unit for blood collecting,
improved “hold over time”for refrigerators and a
review of alternate energy sources for refrigera-
tor and freezers.
Indicators to measure performance include the
number of countries or health care centres ensur-
ing safe blood transmission to patient by imple-
menting a BCC service;the numbers of BCC
equipment tested;the numbers of blood trans-
portations done with blood time temperature
indicators.
Essential surgical procedures at district
hospitals
District surgical services should be able to man-
age the majority of patients with trauma and
Use
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obstetric,orthopaedic and abdominal emergen-
cies.Many first-referral level facilities in develop-
ing countries do not have specialist surgical
teams and are staffed by medical,nursing and
paramedical personnel who perform a wide
range of surgical procedures,often with inade-
quate training.This contributes to unnecessarily
high rates of maternal mortality and death and
disability resulting from trauma.
This project aims at ensuring that medical offi-
cers and other personnel responsible for surgical
and anaesthetic care at first-referral level receive
appropriate training in the skills required for the
management of trauma and common surgical
and obstetric emergencies.
The activity will include:
  Identification of future requirements in train-
ing in surgery and anaesthesia at first-referral
level in developing countries
  Development of a global strategy for
essential surgical care 
  Development of a comprehensive set of
learning materials for use in in-service train-
ing,short courses,basic and continuing edu-
cation programmes for medical,nursing and
paramedical personnel
  Advocacy to promote the development of
national standards and clinical guidelines on
acute surgical care
  Capacity-building through the establishment
of a team of Regional Facilitators to promote
and support the development of national
training activities in acute surgical care
  Organization of regional and inter-regional
workshops to promote both the recognition
of the special training needs of surgical and
anaesthetic personnel at first-referral level
and the provision of appropriate training in
both basic and continuing education
programmes
  Establishment of an Expert Panel on Essential
Surgical Services
  Strengthening of collaborative partnerships
between WHO,non-governmental organiza-
tions and WHO Collaborating Centres in the
development of integrated approaches to
training.
Indicators for this activity include the number of
countries that develop national standards and
clinical guidelines;the number of countries that
establish specialized training programmes in
acute surgical care;and the number of countries
that use the WHO learning materials as part of
their overall training strategy.
Information technology in transfusion
safety
The objectives of this activity are to provide
national blood transfusion services with tools to
help in the implementation of computerized
information management systems.Such tools
will help to reduce transcription errors,improve
records and traceability and increase effective-
ness of donor recruitment and management.We
will also develop guidelines on evaluating the
relevance of computerized information manage-
ment and implementation in blood transfusion,
as well as specifications for blood transfusion
software and a guide for validation.
Training programmes and training material
in diagnostic imaging
A major reason for the non-functioning or mal-
functioning of diagnostic imaging services in
many countries is the lack of proper education
and training,both medically and technically,of
those involved.The objective of this activity is
thus is to improve local knowledge and skills by
developing and implementing adequate training
programmes and training materials.This would
be done in close collaboration with international
and national experts,and with the concomitant
establishment of regional and national centres of
excellence for diagnostic imaging services.
Specific targets include:the establishment of
centres of excellence for education and training
in diagnostic imaging (two in the WHO African
Region,two in Central and South America,one in
South-East Asia,and one in the Western Pacific
Region);the further development,distribution
and implementation of both medical,technical
and managerial training material and pro-
grammes targeting the need of small hospitals
and clinics with limited resources as well as
updated material for the proper use of the World
Health Imaging System for Radiography.
Among the indicators for this activity are the
number of hospitals/institutions with properly
functioning diagnostic imaging,and the numberof hospitals/institutions with sufficiently trained
staff.
Access to medical devices,R&D and
technology transfer to developing
countries
Since about 90% of the world’s medical devices
are produced in Europe,Japan and the United
States of America,we could improve the access
to medical devices by facilitating the transfer of
technology so that local production is stimulated
in the rest of the world.
The objective is to work with manufacturers,gov-
ernments,and users to allow developing coun-
tries to have more equity and better access to
safe and effective medical devices and clinical
technologies.This activity includes a range of
technical and educational projects,some of
which are more “product-oriented”(relating to
the evaluation,and research and development,of
new medical devices in partnership with indus-
try),while the other projects are more “service-
oriented”(involving the provision of tools for a
better access to technology,learning material,
and guidelines for an appropriate and safe use of
technology).
Specific activities include:the harmonization of
the relevant nomenclature and device classifica-
tion systems by using for the Global Medical
Device Nomenclature System (GMDN);regional
information-gathering and needs assessment
meetings;guidelines for the procurement of
medical devices;the elaboration of a communi-
cation/advocacy/funding strategy for medical
devices;the development and evaluation of new
technologies (e.g.,a low-cost blood transporta-
tion box);the measure of the impact of the reuse
of medical devices (including safer use of injec-
tions,safe refurbishment of medical devices);the
strengthening of local capacity to produce
equipment and supplies (WHO bulk procure-
ment system for medical devices including AD
syringes;the technology transfer for local pro-
duction of medical devices,including AD
syringes,meeting with manufacturers on tech-
nology transfer to developing countries);the pro-
motion of appropriate technologies for district
surgical services (oxygen concentrators,
orthopaedic appliances,skills training) and the
production of distance learning materials for
essential surgical care for district surgical services
at first referral hospital (manuals for district level
surgical procedures on anaesthetics,surgery,
trauma,orthopaedics,and obstetrics).
Among the indicators available to measure this
activity are the number of countries implement-
ing WHO guidelines and recommendations for
selection,use,and maintenance of technologies;
the number of new devices developed;and the
number of new devices and new techniques
evaluated (including a “universal blood trans-
portation box”to be developed in partnership
with a Swiss school of engineers).
Management and maintenance of health
care technology
This activity will be carried out in collaboration
with the Department for the Organization of
Health Services Delivery to help health authori-
ties in the process of needs assessment,planning,
selection and acquisition of health care technolo-
gies.It includes the development of technology
management toolkits,one of which is a software-
based planning and management tool called the
Essential Health care Technology Package (EHTP).
A pilot project on Health care technology man-
agement and maintenance started in
Mozambique including a country situation analy-
sis and first sensitization of the MOH to the EHTP.
This activity aims at:
  Supporting the field testing of this software-
based planning and management tool in
some selected countries:Mozambique,
Tunisia,China and others
  Contributing to the finalization and imple-
mentation of the EHTP.
The other part of the project will be built on the
WHO Guidelines for Health care Equipment
Donations.The specific activities include the sup-
port and promotion of the improved process of
technology transfer,particularly with regard to
equipment donation,through application of the
WHO Guidelines on Equipment Donation.The
maintenance information system developed in
Mozambique will also be tested for exportation
to other countries.
24
WHO
Blood Safety and 
Clinical Technology: 
2000–2003 Strategy 25
WHO
Blood Safety and
Clinical Technology: 
2000–2003 Strategy 
Among the other activities are:the development
of learning materials on management of health
care equipment (guidelines on safety,care,main-
tenance and use of medical equipment at district
hospital level);the support on specific preventive
maintenance including blood bank,laboratory
and X-ray equipment.
The impact of the project will be measured by:
the number of appropriate equipment dona-
tions;the reduction of the number of unused
equipment,the number of countries using a
management and maintenance information
system;the number of countries using the EHTP.
Health care waste management
In many countries,the improper management of
wastes generated in health care facilities has a
direct impact on the health of the community,of
the personnel working in health-care facilities,
and on the environment.In addition,pollution
caused by the inadequate treatment of waste
can also have indirect effects on community
health.The disposal of certain types of clinical
devices should follow specific safety rules.For
example,a syringe is a common item that
requires safe disposal.
Health care waste management (HCWM) includes
the management of discarded blood,blood
transfusion bags,laboratory sample,sampling
equipment,waste generated by diagnostic imag-
ing,and devices (e.g.,syringes and needles).
There has been an increasing demand for WHO
to take an active role in implementing safe
HCWM on a larger scale.
Waste management options need to be efficient,
safe and environment-friendly in order to protect
people from voluntary and accidental exposure
to waste when collecting,handling,storing,trans-
porting,treating or disposing of waste.
The main objective of this activity is to determine
how health care waste management is being car-
ried out and how to improve it.The activity will
include:the identification of centralized waste
management and disposal resources available;
the proposal of a choice of management and dis-
posal options (which will depend on their afford-
ability,sustainability,environmental friendliness,
efficacy,on the worker’s safety and in order to
assure the prevention of re-use);and the identifi-
cation of appropriate options for all levels of
health care facilities.
This activity,which is the result of collaboration
with the WHO cluster on Sustainable
Development and Healthy Environments,aims to
focus on waste blood and any waste materials
containing,or which have contained,blood
regarded as hazardous waste for a specific contri-
bution to global blood safety
Steps in the process require a comprehensive
approach and considerable resources.A global
action plan for the implementation of the strat-
egy to reduce disease burden caused by inad-
equate HCWM will have the following targets:
  Evidence and information for policy (a data
base on health care waste management will
be organized to evaluate practices and
options available and for the monitoring of
country progress)
  Reference and guidance material (including
guide,a primary health care decision making
guide,an aide-memoire on HCWM)
  Safety and availability of waste management
options (an Internet-based database,with
field tests for health care waste management
options) 
  Country plans (implementation of waste
management system,national workshops).
Our contribution to this activity will include:the
development of literature search and a review of
health impacts from microbiological hazards in
health care wastes;the preparation of a guidance
document for the appropriate management of
blood waste and waste contaminated with blood
and a primary health care decision-making guide.
The medical device industry is expected to be
among the partners in this activity,and encour-
aged to develop more environmentally friendly
health care products.
Indicators for the success of this activity will
include the number of countries with safe waste
management systems implemented;the number
of primary health care centres currently using the
decision-making guide;the number of options
available for safe health care waste management;
the number of successful cases of technology
transfer in waste disposal. ❒27
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Key Initiatives
Global Collaboration
for Blood Safety 
Each national government has the
responsibility to ensure a safe and ade-
quate supply of blood and blood prod-
ucts for its citizens. However, there are
many parts of the world where the safe-
ty and adequacy of the blood supply is
lacking. Global blood safety requires
urgent attention, and it is only through
improved collaboration between organi-
zations and institutions involved in the
area of blood safety that the safety of
the global blood supply can be
improved.
The recommendations made at the
AIDS Summit of December 1994 in this
respect were reinforced by a resolution
of the World Health Assembly in 1995
(WHA 48.27). Taking up the initiative,
WHO proposed that a broadly constitut-
ed forum in which to communicate and
to propose joint and complementary
action would lead to the required
improved collaboration. This forum
could include national and international
organizations involved in blood and
blood product safety; manufacturers of
plasma, plasma derivatives and blood
devices; users and prescribers of blood;
blood donor organizations, source plas-
ma donors and recipients of blood and
blood products. 
The collaborative mechanism will
build on existing knowledge and con-
ventional wisdom in the area of blood
safety; utilize existing expertise; pro-
mote dialogue on blood safety issues;
and suggest realistic, effective and prac-
tical mechanisms to improve blood and
blood product safety. The collaboration
should be one of representation offering
the opportunity to discuss and suggest
viable solutions to resolve blood safety
issues. Fundamental to improving col-
laboration on blood safety will be the
issue of improving collaboration
between the developed and developing
regions of this world. Developing coun-
tries will have representation in the
mechanism to help identify and offer
realistic approaches to priorities in
blood safety. 
In October 1995, WHO held the First
Preparatory Meeting for the Formation of
a Task Force for Global Collaboration for
Blood Safety in Geneva, to prepare a pro-
posal. The meeting involved most of the
major organizations and institutions
involved in the area of blood safety and
it reviewed the WHO proposal and for-
mulated recommendations for a mecha-
nism to improve global blood safety. The
first full meeting of the Global
Collaboration of Blood Safety (GCBS) was
held in November 2000 and the follow
up Working Group meeting and Annual
meeting will be held in 2001. During dis-
cussions, the meeting agreed on a title
for the collaborative mechanism and on
the following recommendations:
Recommendations for the
formation of the Global
Collaboration for Blood Safety
(GCBS)
Goal: Promote and strengthen international
collaboration on safety of blood products and
transfusion practices.
On 1 December 1994, the Paris AIDS
Summit declared the GCBS should be
established, and consequently the forty-
eighth World Health Assembly, held in28
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May 1995, produced resolution WHA
48.27 covering the formal establishment
of GCBS. The following mission was
adopted:
To improve collaboration among organi-
zations and institutions involved in the
area of transfusion safety with a view to
encouraging and facilitating information
exchange,promoting standards for good
manufacturing practices for blood and
related products for transfusion,and fos-
tering the establishment and implemen-
tation of cooperative partnerships to
ensure donor and recipient safety in all
countries.
GCBS (structure and functions)
It is recommended that to ensure an
effective and efficient GCBS, it should
be made up of a small number of spe-
cialists and representatives of interna-
tionally recognized organizations and
institutions involved in the area of trans-
fusion safety, as well as national repre-
sentatives of different global regions.
The GCBS should ideally comprise
the following organizations:
Participants
1. American Association of Blood
Banks (AABB);
2. European Plasma Fractionation
Association (EPF A);
3. Fédération internationale des
Organisations de Donneurs de Sang
(FIODS);
4. International Federation of Red
Cross and Red Crescent Societies (IFR-
CRCS);
5. International Plasma Products
Industry Association (IPPIA);
6. International Society of Blood
Transfusion (ISBT);
7. World Federation of Hemophilia
(WFH); 
8. World Health Organization (WHO)
(Blood Safety unit, Biologicals unit,
Health Laboratory Technology unit); 
9. Participants from developing coun-
tries to ensure appropriate regional rep-
resentation; 
10. Representation of relevant health
industry manufacturers/medical devices;
and 
11. Representation of prescribers of
blood and blood products.
Observer Participants
1. Commission of the European
Communities (CEC); 
2. Council of Europe (CE);
3. Food and Drug Administration (FDA),
United States of America; and
4. National Institute of Health (NIH),
Japan.
Key points related to the constitution
and operation of GCBS are as follow:
  Subject to sufficient funds being
made available for that purpose,
the GCBS Secretariat will be pro-
vided by the Blood Safety unit of
the World Health Organization
  The GCBS will elect a chairman
for a one-year to two-year term.
The functions and activities of the
chairmanship will be decided at
the first meeting of the GCBS 
  The GCBS will hold at least one
to two meetings per year, with
dates agreed by a majority deci-
sion of the members 
  The GCBS will produce and dis-
seminate documents which,
among other things, analyze
problems and advocate research
to find solutions relating to trans-
fusion safety. The GCBS will form
and utilize the expertise of ad hoc
Working Groups to debate specif-
ic issues relating to blood and
blood product safety and to pro-
vide recommendations and guid-
ance to the GCBS. In some
instances, the Working Groups
may need to be formally consti-
tuted and required to meet to
reach consensus on particular
issues. In other cases, a Working
Group may be constituted less
formally and carry out its task by
correspondence 
  The GCBS will make the decision
on the functions and activities of
each Working Group and make
appropriate provision for the
costs involved in each taskassigned, (i.e., a particular organi-
zation such as WHO, IFRCRCS,
ISBT, etc., may be able to carry
out the necessary task through its
plan of work and budget for
blood safety activities. In other
cases a project proposal may
need to be developed to seek
funding for a specific Working
Group activity).
GCBS funds
Funds will need to be raised to support
the GCBS activities, i.e., from govern-
ments, non-governmental organizations
and, if necessary and appropriate, from
the private sector. With regard to poten-
tial financial support from the private
sector, care should be taken, however,
to avoid the risk of actual or perceived
conflicts of interest. Commercial donors
should not seek promotion of the fact of
their donations. In this regard, the partic-
ipants in the GCBS will need to ensure
that all fund-raising efforts are in accor-
dance with their respective policies and
principles. Under the direction of the
GCBS, the WHO Blood Safety unit will
administer financial contributions intend-
ed to support the activities of the GCBS
through a trust fund entitled Global
Collaboration for Blood Safety. This trust
fund will be administered in accordance
with WHO’s financial regulations, rules
and practices and be subject to WHO’s
normal programme support costs.
Periodic financial reports will be provid-
ed by the Secretariat to the membership
of the GCBS, justifying how funds desig-
nated to support the activities of GCBS
have been used. 
The formation of, and participation
in, the GCBS may, however, dependent
on how much funding is available in the
above-mentioned trust fund, require
financial commitments from some or all
of the participants.
GCBS objectives
The GCBS objectives are as follow:
  to promote international consen-
sus on essential principles of
global blood safety;
  to promote the improvement of
global blood safety and encour-
age governments to recognize
and establish national blood pro-
grammes;
  to assist countries, upon request,
to identify national blood safety
priorities and prevent transfusion
transmitted disease;
  to assist countries, upon request,
in the implementation of appropri-
ate and recognized transfusion
practices to ensure donor and
recipient safety and freedom from
discrimination;
  to promote effective recruitment
of safe donors through the use of
appropriate selection criteria;
  to promote the appropriate prepa-
ration and utilization of blood and
blood products; 
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Figure 5: GCBS – WHO Secretariat
Figure 6: GCBS – Partners and WHO Secretariat
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  to encourage safe international
practices for the collection, stor-
age and transport of plasma and
the preparation and distribution of
its derivatives;
  to promote the bi-directional
traceability of blood products
between donor and recipient
whether in-country or across
national borders; and
  to facilitate the exchange and use
of information by encouraging
data collection, management and
dissemination. 
The development of GCBS
The Department of Blood Safety and
Clinical Technology continues to host
the secretariat of the GCBS, bringing
together national and international
organizations involved in blood and
blood product safety; and associations
of manufacturers of plasma, plasma
derivatives and blood devices and diag-
nostics, of prescribers, users, and recipi-
ents of blood and blood products as
well as blood donor organizations.
In the short term, a review of exist-
ing safety interventions along the trans-
fusion chain will be carried out with a
view to devising and agreeing on an
objective assessment framework. This
will constitute a tool for developed and
developing countries to prioritize inter-
vention strategies, and it will help deci-
sion-makers.
Safe Injection Global
Network 
While it is the responsibility of each
national government to ensure safe and
appropriate injections, prevention of
adverse events associated with injec-
tions will require improved collaboration
between organizations and institutions
sharing a common interest in this goal.
The Safe Injection Global Network
(SIGN) is a new mechanism for coordi-
nating activities aimed at the safe and
appropriate use of injections worldwide.
Unsafe injections waste pre-
cious health care resources 
A literature review published in 1999
indicated that, of all medical proce-
dures, injections are probably the most
common. About 12 000 million injec-
tions are administered each year
throughout the world. Less than 10% are
for immunizations. Many of the thera-
peutic injections, the widest application,
could be avoided. In many countries,
both patients and health care workers
prefer medicines to be administered by
injection. Reportedly, patients ask for
injections because they believe that
medication is more efficacious by that
route and that the pain of the injection
is a marker of that efficacy. Reasons for
health care workers to inject excessive-
ly include the desire to respond to a
perceived patient preference, the wish
to monitor compliance directly and, in
some instances, the possibility of charg-
ing a higher fee for service. Overall,
unnecessary injections lead to high out-
of-pocket health care expenses for
patients and their families.
Poor injection practices cause
a high burden of disease 
Many injections administered in the
world are unsafe. Of particular concern
is the reuse of injection equipment with-
out sterilization - a frequent practice in
developing countries and those in transi-
tion, where it is common simply to rinse
syringes and needles in containers of
tepid water between injections. In these
countries, injections account for a high
proportion of new infections due to hep-
atitis B and hepatitis C viruses. Each
year, globally, reuse of dirty injection
equipment causes an estimated eight to
16 million infections with hepatitis B
virus, 2.3 to 4.7 million infections with
hepatitis C virus, and 80 000 to 160 000
infections with HIV. Together, these
chronic infections are responsible for an
estimated 1.3 million early deaths and 26
million of years of life lost, and lead to
US$ 535 million in direct medical costs.31
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Poor injection practices can be
eliminated  
To reduce overuse of injections and to
assure safe injection practices, multidis-
ciplinary strategies comprising three ele-
ments should be implemented. First,
there needs to be a change in behav-
iour: patients and health care workers
should be encouraged to adopt safe
practices and to avoid unnecessary
injections. Second, sufficient quantities
of clean injection equipment should be
available in each health care facility.
Third, mechanisms should be in place
so that “sharps” (i.e. needles and
syringes) are so disposed of as to
ensure that dirty injection equipment is
not reused and the risk of accidental
needle-stick injuries is minimized.
Interventions based on each of these
three elements have proven to be suc-
cessful and demonstrated that poor
injection practices can be eliminated.
For example, in Indonesia, behavioural
change interventions have resulted in a
substantial and sustained decrease in
the overuse of injections. In Burkina
Faso, increasing the availability of
clean, disposable injection equipment
through community pharmacies has
almost eliminated unsafe injection prac-
tices. In a pilot project in Côte d’Ivoire,
the introduction of small-scale, locally-
built incinerators and at the same time
training of health care workers have
successfully eliminated dangerous nee-
dles and other sharps waste from the
environment. 
Safe and appropriate use of
injections does not require a
new programme  
In every country, efforts to ensure safe
and appropriate use of injections require
collaboration between all partners.
Because multidisciplinary interventions
are needed, the basis of preventive
activities should be careful coordination
of already existing initiatives rather than
the creation of new programmes.
National health authorities responsible
for health promotion, HIV prevention,
integrated management of childhood ill-
nesses and blood transfusion services
should promote safer behaviour among
patients and health care workers.
Similarly, national authorities responsi-
ble for access to essential drugs, immu-
nization services and family planning
should increase the availability of clean
injection equipment. It is recommended
that responsibility for safe management
of health care waste should be
assigned to health care services.
WHO activities for the safe and
appropriate use of injections  
Because unsafe injections waste pre-
cious health care resources, transmit
bloodborne pathogens on a large scale
and can be eliminated, WHO has
increased its activities to improve injec-
tion safety. First, WHO hosts the secre-
Figure 7: SIGN Associates and SIGN Secretariat
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tariat of the Safe Injection Global
Network, a coalition, created in 1999, of
stakeholders who strive for safe and
appropriate use of injections worldwide.
Working within a common strategic
framework, the secretariat coordinates
the activities of the network. Second,
WHO has coordinated its relevant activi-
ties, which include safety of immuniza-
tion injections, rational use of medi-
cines, blood transfusion safety, labora-
tory safety, medical devices, manage-
ment of health care waste, prevention
of viral hepatitis, and prevention of
injection drug use.
Quality Management
Project for Blood
Transfusion Services 
General Background   
Quality management in all areas of
blood transfusion is crucial for the provi-
sion of safe blood for all those requiring
transfusion. In most developing coun-
tries, there is a lack of quality manage-
ment for the safety of blood and blood
products which adversely affects the
quality of care to the patients. WHO has
identified that urgent attention and
action needed to be devoted to quality
in the blood transfusion services. 
In order to implement a quality sys-
tem, the capacity of the Blood
Transfusion Services (BTSs) needs to be
improved through comprehensive train-
ing. There is an acute shortage of
trained manpower in blood transfusion
in developing countries. Quality man-
agement has therefore been identified
as a key strategy for global blood safety
and has been targeted by WHO as a pri-
ority for training. 
WHO has developed the Quality
Management Project (QMP) as a new initia-
tive to be carried out in all regions start-
ing from 2001 as a part of a strategy for
building capacity at global level. The
project addresses the need to adopt the
principles of quality management in all
areas of the blood transfusion services
in order to ensure good organization
and management, donation from safe
blood donors, testing of all donated
blood for HIV and other transfusion
transmissible infections (TTI), quality
component production and appropriate
clinical use of blood. This project aims
to ensure the safety of blood transfu-
sions to significantly reduce mortality,
morbidity, and the global disease bur-
den due to the transfusion of infected
blood and blood products. 
QMP has been developed as a long-
term collaborative and sustainable proj-
ect with effective co-operation and col-
laboration with other international organ-
izations already involved in quality man-
agement such as the American
Association of Blood Banks,
International Federation of Red Cross
and Red Crescent Societies, and the
International Society of Blood
Transfusion.
Activities have been planned for all
the WHO regions, focusing on promot-
ing the principles of quality systems
and assisting blood transfusion services
and national authorities in implementing
quality systems.
Goal
To build capacity in the area of quality
management for blood transfusion
services covering all aspects of blood
transfusion, through an integrated
approach of training and assessment, in
all member states of WHO with regional
cooperation.  
Figure 9: Quality Management Project
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Objectives
  To assist WHO Member States in
improving the quality, safety and
adequacy of blood 
  To upgrade national capacity,
knowledge and skills of WHO
member states in all aspects of
quality management in blood
transfusion through regional train-
ing courses
  To establish regional quality train-
ing centre(s) for ongoing training
for BTSs in each WHO region
  To develop regional external qual-
ity assessment schemes (REQAS)
in coordination with international
external quality assessment
scheme for TTI and blood group
serology 
  To upgrade the facilities and build
a Quality Area Desk in BTS at
national level
  To establish a sustainable nation-
al quality system in BTS in each
Member State.
Activities
  Identify quality training centre(s) in
each of the WHO region which
will be responsible for organizing
regular Quality Management
Training (QMT) courses in all
aspects of blood transfusion
  Organize QMT courses for blood
transfusion services 
  Establish REQAS with the coun-
tries participating in the training
course for TTI and blood group
serology, integrated within the
training courses in quality man-
agement for BTS
  Develop an effective quality net-
work for BTS between the region-
al quality training centre and the
participating centres. 
Quality Management Training
for Blood Transfusion Services
Considering the need to train staff in
blood transfusion services, Quality
Management Training (QMT) constitutes
an important component of the project.
QMT essentially includes organization of
4-week training courses and post-train-
ing support and follow up to the partici-
pants of the courses to assist them in
implementing their plans of action for
establishing quality systems in their
blood transfusion services. The partici-
pants will also be a resource for estab-
lishing the national quality systems in
BTSs.
Objectives
  To assess current status of quali-
ty system in blood transfusion
services in the participating
countries
  To develop the participants’
knowledge and skills in quality
assurance
  To improve knowledge and skills
in good laboratory practices
  To develop a plan of action for
implementation of quality system
for the participants’ BTS/Blood
Bank
  To suggest future requirements
for continuous training and
staff development in quality
management.
Participants’profiles
The profiles of the participants attending
the courses organized by the training
will be adapted to the different types of
courses organized. Two categories of
Figure 10: Components of QMP
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participants from the countries in the
region should be nominated for each of
these courses. The basic requirements
are:
  a qualification in Medical
Laboratory Sciences preferably
with specialized training in
Immuno-haematology/Blood
Transfusion
  the participants should be current-
ly working full-time in a Blood
Transfusion Service or a Blood
Bank with sufficient supervisory
experience in blood transfusion
safety/blood transfusion
service/blood bank 
  it would be an added advantage
if the participant has experience
in management skills and quality
assurance and a basic knowl-
edge of the aspects of blood
transfusion science other than
laboratory/technical matters i.e.
blood donation practices, compo-
nent production, and the techni-
cal aspects of use of blood in
clinical situations.
The number of participants in each
course will depend on the number of
countries in the region as well as the
size of the countries. At least, two par-
ticipants will be selected initially from
each country. However in large coun-
tries, there would be a need for a coun-
try-specific QMT.
Participants should be able to take
on the role of quality manager/officer
after attending the course. The partici-
pants will be expected to initiate and
strengthen the implementation as well
as monitoring of the quality systems in
their own BTS as well as contribute in
developing national quality systems. 
Methodology of work
Each year, two or three 4-week courses
will be organized. Participants from the
countries in the region could be nomi-
nated each year for the training course.
The training course will be organized in
a modular form, covering general quali-
ty context and quality principles applied
to specific areas in BTS.
A curriculum has been developed
for the QMT courses after several con-
sultative discussions and appropriate
training materials is being developed
according to the final curriculum, con-
sidering the different level of knowledge
and skills of the participants. Back-
ground material for the case studies and
group activities is also being prepared. 
The training courses consist of for-
mal lectures, case study exercises and
group activities. In addition to the staff
of the training centre and WHO’s techni-
cal assistance, external facilitators will
be used to cover specific topics within
their area of expertise. Prior to the train-
ing course participants will receive a
questionnaire to assess their BTSs. The
knowledge of participants will be
assessed at the beginning, during and
at the end of the course. Sufficient time
will be devoted to enable participants in
developing a one-year follow up action
plan to improve their BTSs. The con-
cept of regional external quality assess-
ment schemes (REQAS) will be intro-
duced to the participants and centres
participating in REQAS will be identified.
Depending on the evaluation of the
4-week course and the participants’
needs, one or two 2-week refresher
course(s) will be organised dealing with
specific aspects of quality in blood
transfusion such as intensive courses in
TTI, blood group serology, quality in
blood component production, etc.
Considering the regional variations, the
training courses could be adapted to
the regional needs for training.
Mechanisms will be developed to
assess the implementation of action
plan by the participants as well as to
assist them in overcoming the problems
faced in implementation of the action
plan.
Expected outcome
  Participants will acquire the
knowledge and skills to establish
quality system for blood transfu-
sion services/blood banks
  Knowledge and skills in good lab-
oratory practices will be
improved35
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  The current status of the quality
system in blood transfusion serv-
ices will be assessed in the par-
ticipating countries
  A plan of action for implementa-
tion of quality system for the par-
ticipants’ BTS/Blood Bank will be
developed
  Future requirements for continu-
ous training and staff develop-
ment in quality management will
be proposed.
Establishing a Regional Quality
Training Centre in each WHO
Region 
In most of the WHO regions, one of the
WHO collaborating centres in blood
transfusion or one of the national institu-
tions working in the area of blood safe-
ty has been identified by WHO to under-
take training in quality management for
blood transfusion services. The identi-
fied centres should have facilities for
training such as lecture rooms, office
space for facilitators, communication
means, including Internet access, dis-
tance teaching, multimedia, a laboratory
for trainees and dedicated staff to take
over the responsibility of organizing the
training courses. Ideally, the centre
should also have facilities for accommo-
dation for the trainees. For those
regions where such a training centre
does not exist, a centre may need to be
upgraded to carry out this task.
Depending on the requirements of the
centre, the facilities may need to be
upgraded for ongoing training activities
with the assistance of WHO. The centre
would be strengthened through upgrad-
ing its training facilities, provision of lab-
oratory equipment and appointing full-
time training facilitators. An area in the
centre should be dedicated for the
preparation of REQAS materials and
training of BTS staff from the countries
identified for the project.
In addition to providing training for
the participants from the blood transfu-
sion services in the region, the regional
quality training centre or another identi-
fied centre with previous experience of
organizing quality assessment schemes
will take the opportunity to establish the
regional EQAS and assist in establishing
national external quality assessment
scheme. 
The training centre will not only also
act as a regional resource training cen-
tre but also hold annual meetings of
quality managers and be seen as an
instrument to promote networking in the
region in the area of blood transfusion
safety.
Establishment of Regional
External Quality Assessment
Schemes 
Regional External Quality Assessment
Schemes (REQAS) will be established
which would be introduced within the
quality management training and have
been integrated within the quality man-
agement project. The aim of this inte-
grated approach of providing training
courses and introducing REQAS at the
same time, is to enable participating
BTS in upgrading their knowledge and
expertise and at the same time provid-
ing them with the information about the
need and role of EQAS in improving the
performance of their laboratories.
Objectives
  To develop regional external qual-
ity assessment schemes which
would be integrated with interna-
tional external quality assessment
scheme for transfusion transmis-
sible infections and in blood
group serology
  To improve national quality sys-
tems by assisting WHO Member
States to establish national EQAS
  To assess the quality of laborato-
ry performance on a
national/regional level.
The participants in the QMT course
will be identified as the focal points for
participating in the WHO regional exter-
nal quality assessment schemes for
transfusion transmissible infections (HIV,
hepatitis B, hepatitis C) and blood group
serology (ABO & Rh D grouping and36
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cross- matching). The IEQA panels will
be sent by WHO/HQ to REQAS organis-
ers who in turn will send their panels
initially to participating laboratories, two
or three times a year. Subsequently the
capacity of the organizing centres will
also be strengthened to enable them to
prepare their own proficiency panels
and bring them into conformity with the
international standards.
Methodology of work
At the refresher training course the
results of the REQAS will be discussed,
and special emphasis will be given to
the identified problem areas. In addition,
the plan of action will be reviewed with
each of the participating BTS and an
evaluation of the progress (failures and
achievements) will be made. Possible
solutions for the problems and difficul-
ties encountered will be sought. The
Plan of Action will be revised based on
the evaluation results of REQAS, and
the establishment of the national quality
system will be promoted. 
Establishment of Regional
Quality Network in Blood
Transfusion Services
Today, most blood transfusion services
in the developing countries work in iso-
lation. There is a need for mutual com-
munication and access to information
through newsletters and networks for
BTS. Training in quality management
and provision of necessary information
technology packages will make it possi-
ble to achieve the goal for blood safety
and will substantially contribute to
improving blood safety globally. This is
one of the seven priorities of WHO. 
Objectives
  To develop a formal structure for
interaction between Regional
Quality Training Centres and
blood transfusion services in
countries in the region, in partner-
ship with collaborating centres
experts and non-governmental
organisations, for the effective
implementation of quality man-
agement systems at the national
level
  To develop and upgrade the facili-
ties of information technology for
interaction between BTS at
regional, sub-regional and country
level, including policy makers,
WHO collaborating centres and
non-governmental organizations
  To create effective electronic
national networks to enable the
sharing of critical resources in
blood transfusion services such
as the blood donor database,
information on blood collection,
testing of blood units, inventory
of blood and its components,
availability of technical expertise,
and information on issuing and
utilization of blood
  To provide on-line assistance to
BTS and facilitate training in
blood safety.
Activities 
  Equip major blood transfusion
services with hardware (desktop
computer, printer, continuous
power unit), software and Internet
access
  Train the participants in computer
skills: development of skill for
information access and manage-
ment, application of information
technology to blood transfusion
services, and its utilization for
developing an effective electronic
network system
  Provide access to have informa-
tion on the Internet, download rel-
evant technical knowledge, use e-
mail for exchange of information
and for problem solving, and use
voice/telephone facilities to
encourage teleconferencing.
Given access to information on the
Internet, participating centres will be able
to communicate with the regional quality
training centre, download relevant techni-
cal material, receive newsletters and
training materials, get information on
EQAS and receive the results of EQAS.37
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The establishment of a regional quality
network in blood transfusion services
will lead to improvement in the safety,
accessibility and quality of blood supply. 
Expected outcomes 
  The Quality Management Project
for Blood Transfusion Services is
developed as a six-year project
(2000-2005) and expected out-
comes are reviewed every year
  At least two persons from each
country in every region will have
been trained every year as quality
managers/officers
  The regional quality training cen-
tre(s) will be established for ongo-
ing quality management training
for BTSs. Based on the needs,
the identified regional quality
training centre will be strength-
ened in terms of infrastructure,
equipment and staff in order to
improve the capacity for training
  Member States in each WHO
region will participate in Regional
External Quality Assessment
Schemes
  Member States will have estab-
lished a sustainable national qual-
ity system including a national
EQAS
  The facilities in a Quality Area
Desk in BTS will be upgraded
  All donated blood will be ade-
quately tested for HIV and other
TTIs, blood group serology,
processed using good laboratory
and manufacturing practices in at
least 80% countries of the region
by 2005, on a consistent basis
  The quality, safety and adequacy
of blood will be improved in all
Member States.
Monitoring and evaluation
Among the indicators used to assess
the performance of this project will be
the following:
  Number of participants trained
per country
  Proportion of countries trained in
the region
  Number of training courses held
as per plan
  Quality of the training course
developed
  Participants’ satisfaction with the
course
  Use of the centre as a resource 
  Improvement in quality of work at
the BTSs of the participants’ after
6 month/1 year of training 
  Number of centres participating in
the REQAS and of centres show-
ing satisfactory performance
  Number of centres taking correc-
tive measures
  Number of centres provided with
the facilities for electronic net-
working
  Number of centres using electron-
ic network facilities.
Providing Appropriate
Diagnostic Support in
HIV/AIDS Control
Providing diagnostic support is an
essential part of ensuring quality health
care in the fight against the HIV/AIDS
pandemic. There has been a strong call
for access to drugs to help in the fight
against HIV, however, it must be remem-
bered that this battle is a process which
does not only require access to treat-
ment, but also access to accurate diag-
nostics, quality of care and follow up.
The diagnostic support activities of the
BCT play a vital role in all three phases
of this process. 
Using appropriate diagnostic tech-
nology for screening and diagnosis is the
starting point in the process. In addition
to the actual diagnosis of patients’ HIV
status, diagnostic technology must be
used for screening of donated blood to
prevent transmission through transfu-
sion. Diagnostic tests are also instru-
mental for surveillance, providing epi-
demiological data to monitor the spread
of the HIV/AIDS epidemic. Use of reli-
able tests and appropriate testing strate-
gies are important in the prevention of
mother-to-child transmission, and for
voluntary counselling and testing38
WHO
Blood Safety and 
Clinical Technology: 
2000–2003 Strategy 
services. In these settings, simple/rapid
diagnostic tests can provide accurate,
same-day diagnosis resulting in timely
treatment where needed. 
Once individuals are identified as
being infected with HIV, and/or related
opportunistic infections, diagnostics
are used to determine the appropriate
treatment intervention. For example,
diagnostic tests may indicate resistance
to certain drugs and thus provide guid-
ance on appropriate drug regimes.
Subsequent diagnostic technologies are
required to monitor the safety and effec-
tiveness of treatment on a continuing
basis. Additional diagnostic imagine and
basic clinical laboratory tests will pro-
vide information to ensure the ongoing
quality care and support provided to those
infected with HIV and suffering from
associated infections and illnesses such
as TB. 
Several key activities within BCT
contribute to the provision of high quali-
ty cost effective health care as related
to the HIV epidemic.
BCT aims to ensure that the diag-
nostic technologies used in diagnosis
and screening meet the highest stan-
dards, and that they are available and
used appropriately. The operational
characteristics of HIV test kits are evalu-
ated, and reports providing technical
information on their quality are issued
regularly. Alternative HIV testing strate-
gies for the various testing objectives
have been developed, and are updated
as required. The WHO HIV Test Kit Bulk
Procurement Scheme facilitates access
to high-quality, low-cost diagnostic tests
to Member States and UN agencies.
BCT is assessing the available tech-
nologies for monitoring the efficacy of
HIV treatment (CD4, p24, and viral load
testing) that are suitable for countries
with limited facilities and resources.
Tool kits for clinical laboratory monitor-
ing at the district hospital (1
st referral)
and centralized referral hospital (2
nd
referral) levels are currently being devel-
oped. To ensure reliable results, existing
schemes for monitoring laboratory per-
formance will also be expanded to
cover all HIV related diagnostic areas.
BCT is also providing guidance and
training to support and improve health
care services, in areas of blood safety,
clinical laboratory and diagnostic imag-
ing, all of which contribute to improved
quality of care. Capacity building to
improve skills and knowledge at all lev-
els for appropriate diagnostic support is
an overarching aspect of BCT’s activities.
Many of these BCT activities are car-
ried out in collaboration with other WHO
departments to improve synergies and
with UN agencies such as UNAIDS and
UNICEF , WHO Collaborating Centres and
key international partners. These part-
nerships are, and will continue to be, an
integral part of BCT’s response to the
HIV/AIDS pandemic.  ❒
Figure 11: Appropriate diagnostic support with an emphasis
on HIV and related diseases,and collaboration with
partners
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Information, Education,
Communication and
Resource Mobilization
Strategy
Information, Education
and Communication 
The Department of Blood Safety and
Clinical Technology has a challenging
programme of work over the four-year
period covered by this Strategic Plan to
achieve the objectives and targets set.
The success of our endeavours will
depend, to some extent on available
resources – both human and financial –
and on a coherent communications
strategy.
A small communications team has
been formed within the department to
enhance awareness and visibility of the
work of BCT, to promote the mission
and key messages of the teams, and to
strengthen links between existing and
potential donors and partners at all
levels.
They will focus on ensuring that the
information disseminated is consistent,
credible and communicated effectively
to all relevant audiences in an appropri-
ate format, and using the various chan-
nels available, such as:
  the written medium (technical
documents and guidelines, meet-
ing reports, information sheets
and other advocacy papers,
learning materials, etc.)
  audiovisual support (standardized
presentations, graphic images,
audio and video cassettes)
  electronic mail and Internet
facilities
  personal contact.
The Department will place increas-
ing emphasis on passing information
through its Internet pages and by using
individual and thematic electronic mail
addresses. This endeavour in no way
replaces the need for the printed page,
especially in resource-poor settings
where equipment is often unavailable or
inappropriate. It will however, be an
extremely useful tool to access credible
information, and even fulfil an interactive
role in information sharing – for example
through restricted, extranet pages – or in
distance learning techniques.
The communications strategy will
also target appropriate major interna-
tional events and other types of meet-
ing as valuable opportunities to share
information and enlist support for the
priority activities of the Department.
Networking will also be undertaken
broadly to ensure that government and
nongovernmental organizations alike
have the tools they need to reach their
national objectives in areas related to
blood safety and clinical technology.
Resource Mobilization 
The resource mobilization objective of
the Blood Safety and Clinical
Technology department is ultimately to
secure that the department receives
adequate funding from appropriate
donor sources to allow it to carry out its
planned activities. 
BCT’s activities have largely been
funded by WHO’s regular budget and
the department has historically had only
a few government donors such as
Belgium, Italy, Japan, Luxembourg,
Netherlands and United Kingdom,
providing extrabudgetary support.
Given the scaling up of department
activities, the urgency in addressing
global challenges such as HIV/AIDS or
poor quality management and the40
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increased internal and external
demands made on the department, a
comprehensive resource mobilization
strategy is needed to meet the current
and expected funding gap.
The BCT resource mobilization strat-
egy will form part of the HTP cluster
strategy and build on the experience
and lessons learned from sister depart-
ments. Special attention will be given
to:
  maintaining and increasing extra-
budgetary contributions from
existing donor governments;
  identifying potential new donors
in the public and private sectors;
  finding innovative ways of posi-
tioning department projects in
funding requests within and out-
side WHO; and 
  raising awareness about the
department’s activities within and
outside WHO.  ❒41
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T
he budget and unmet needs
quoted in this section are as at
January 2000. BCT’s 2000-2001 budget
will be adjusted during its implementa-
tion to reflect the actual income.
Changes to the original core budget will
be reflected in a working budget, and
reported at the 2001 session of the
Meeting of Interested Parties.
Annex: Summary
Budgetary Figures
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Figure 12: Additional income required for three priority areas
Norms,
standards
and global
collaboration
Strengthen
national-
regional
capacity-
training
Injection
safety
Operating budget
Gap
Total gap US$ 8.7 m
US$3.5 m
US$3.7 m
US$ 1.5 m
Figure 13: Income expected and unfunded priorities
Unfunded three priorities 58%
Expected income specified 19%
Regular budget 23%
Total gap US$ 8.7 m42
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6 399 2 274 -4 125 1 479 795 0 795
4 044 1 043 -3 001 771 272 0 272
2 192 1 186 -1 006 663 523 0 523
163 45 -118 45 0 00
4 473 2 509 -1 964 1 255 1 254 0 1 254
2 028 1 188 -840 793 395 0 395
2 212 1,078 -1 134 219 859 0 859
233 243 10 243 0 00
512 230 -282 230 0 00
512 230 -282 230 0 00
6 362 1 788 -4 574 787 1 001 0 1 001
3 923 943 -2 980 454 489 0 489
1 075 336 -739 295 41 04 1
616 171 -445 0 171 0 171
748 338 -410 38 300 0 300
17 746 6 801 -10 945 3 751 3 050 0 3 050
1 423 -1 423
19 169 6 801 -12 368 3 751 3 050 0 3 050
2 209 685 1 524 0 1 524
19 169 9 010 -12 368 4 436 4 574 0 4 574
Table 1: Planned cost,core budget and unfunded priorities by objectives and target,and by source of funds,2000-2001,as at January 2000
(all amounts in US$ thousand,inclusive of programme support cost on voluntary contribution)
Policy:To strengthen the capacity of
countries to formulate,implement,monitor,
and update national policies and plans for
blood,blood products,injections,diagnostic,
clinical technologies and medical devices
T1 Formulation,implementation,
monitoring and updating of national
policies and plans
T2 Global collaborations
T3 Global systems to monitor impact
Quality and safety:To assist
countries in ensuring the quality and safety
of blood,blood products,injections,
diagnostic,clinical technologies and medical
devices
T4 Development of norms,standards,
guidelines and reference materials
T5 Research,development and
evaluation of new technologies and
methods
T6 Development and implementation of
national quality systems
Access:To support countries in ensuring
equitable availability and affordability of
blood,blood products,injections,diagnostic,
clinical technologies and medical devices
T7 Continuous and sufficient quantities
of appropriate equipment and
supplies
Use:To promote appropriate and cost-
effective use of blood,blood products,
injections,diagnostic,clinical technologies
and medical devices
T8 Appropriate collection,processing and
clinical use of blood and blood
products
T9 Appropriate use of diagnostic imaging
and laboratory technologies
T10 Safe and appropriate use of injections
T11 Appropriate use of devices and clinical
technologies
Sub-total
Programme support cost on unfunded
area
Total BCT – objective target
Departmental management,advocacy 
and coordination
Grand total BCT
Planned cost
(a)
Total core
budget
(b)
Unfunded
priorities
(c = b - a) Objective • Target
WHO regular
budget
allocation
(d)
Voluntary
contributions
(e = f + g)
Unspecified
(f)
Specified
(g)